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Abstract 
 
Background 
The current paper includes the systematic search of the literature, the detailed 
presentation of the results and the grading of treatment options in terms of efficacy 
and tolerability/safety. 
Material and Methods  
The PRISMA method was used in the search of the literature with the combination of 
the words ‘bipolar’, ‘manic’, ‘mania’, ‘manic depression’ and ‘manic depressive’ with 
‘randomized’, and ‘algorithms’ with ‘mania’, ‘manic’, ‘bipolar’, ‘manic-depressive’ 
or ‘manic depression’. Relevant web pages and review articles were also reviewed. 
Results 
The current report is based on the analysis of 57 guideline papers and 531 published 
papers related to RCTs, reviews, post-hoc or meta-analysis papers to March 25
th
, 
2016. The specific treatment options for acute mania, mixed episodes, acute bipolar 
depression, maintenance phase, psychotic and mixed features, anxiety and rapid 
cycling were evaluated with regards to efficacy. Existing treatment guidelines were 
also reviewed. Finally, tables reflecting efficacy and recommendation levels were 
created which led to the development of a precise algorithm that still has to prove its 
feasibility in everyday clinical practice.  
Conclusions 
A systematic literature search was conducted on the pharmacological treatment of BD 
to identify all relevant RCTs pertaining to all aspects of BD and graded the data 
according to a pre-determined method to develop a precise treatment algorithm for 
management of various phases of BD. It is important to note that the some of the 
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recommendations in the treatment algorithm were based on the secondary outcome 
data from post-hoc analyses. 
Key Words: Bipolar disorder, anticonvulsants, antidepressants, antipsychotics, 
evidence-based guidelines, lithium, mania, bipolar depression, mood stabilizers, 
treatment, clinical trials 
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1. Introduction  
 
The current paper is the second in the series of CINP papers concerning the 
development of a precise algorithm and clinical guidelines for the treatment of 
Bipolar disorder (BD) in adults for use in primary and secondary care. It includes a 
systematic search of the literature and a detailed presentation of the results concerning 
placebo-controlled randomized trials for all phases and aspects of BD. It also includes 
the grading of treatment options in terms of efficacy and tolerability/safety as well as 
a precise algorithm that still has to prove its feasibility in everyday clinical practice. 
 
2. Material and Methods  
 
As described in the first paper concerning the CINP treatment guidelines for BD, the 
workgroup decided that the PRISMA method (Hopewell et al., 2008; Liberati et al., 
2009; Moher et al., 2009) should be followed in the search of the literature. The 
method included the search for three kinds of papers:  
a. Randomized Controlled trials (RCTs; placebo controlled as well as clinical 
trials with an active comparator with the compounds used as monotherapy or 
add-on therapy). 
b. Post-hoc analyses of RCTs 
c. Meta-analyses and review papers 
d. Treatment guidelines papers 
For this purpose the MEDLINE was searched to March 25
th
 2016 with the following 
search strategies: 
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1. In order to locate RCTs, the combination of the words ‘bipolar’, ‘manic’, 
‘mania’, ‘manic depression’ and ‘manic depressive’ and ‘randomized’ was 
used.  
2. Web pages containing lists of clinical trials were scanned. These sites 
included http://clinicaltrials.gov and http://www.clinicalstudyresults.org as 
well as the official sites of all the pharmaceutical companies with products 
used for the treatment of BP. 
3. Relevant review articles were scanned and their reference lists were 
utilized (Srisurapanont et al., 1995; Yatham et al., 1997; Davis et al., 1999; 
Burgess et al., 2001; Macritchie et al., 2001; Bech, 2002; Macritchie et al., 
2003; Rendell et al., 2003; Gijsman et al., 2004; Fountoulakis et al., 2005; 
Gao et al., 2005; Bech, 2006; Cipriani et al., 2006a; Cipriani et al., 2006b; 
Rendell et al., 2006; Smith et al., 2007; Fountoulakis, 2008; Fountoulakis 
et al., 2008a; Fountoulakis and Vieta, 2008; Fountoulakis et al., 2009b; 
Yildiz et al., 2010; Cipriani et al., 2011; Nivoli et al., 2011; Tarr et al., 
2011; Fountoulakis, 2012; Fountoulakis et al., 2012d; Fountoulakis et al., 
2012a; Nivoli et al., 2012; Fountoulakis, 2015b, c, a). 
4. The MEDLINE was searched with the combination of keywords 
‘guidelines’ or ‘algorithm’ with ‘mania’, ‘manic’, ‘bipolar’, ‘manic-
depressive’ or ‘manic depression’. 
5. The treatment guidelines were also scanned and their reference lists were 
utilized  
It is difficult to locate unpublished studies, especially old ones and even more 
difficult to retrieve their results. Thus, the main focus of this paper was on published 
studies which would have been peer-reviewed, are typically of higher quality and 
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provide more details than meeting abstracts or conference reports. However, 
whenever an unpublished trial was located, it is mentioned in that specific part of the 
manuscript. The authors decided not to seek additional information concerning 
unpublished trials from manufacturers as this might increase the retrieval bias. 
Eventually the efficacy data were graded on the basis of a method developed 
by the authors and described in the first paper of the CINP guidelines for BD which is 
also shown in table 1. Agents were graded on the basis of safety and tolerability and 
these grades are also shown in table 1. 
The PRISMA chart of the search process is shown in figure 1 concerning 
RCTs and in figure 2 concerning guidelines. Ultimately the current report was based 
on the analysis of 57 papers related to guidelines and 569 published papers 
concerning RCTs or other relevant papers (reviews, post hoc or meta-analyses).  
 
3. Efficacy data 
 
3a. Acute mania 
 
The data on monotherapy and combination treatment for acute mania are 
shown in table 2. As well, the table also includes grading of efficacy data for various 
features of mania such as psychotic features, mixed features, agitation etc. most of 
which was based on the post-hoc analyses of RCTs. 
 
  
 by guest on N
ovem
ber 17, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pt
ed
 M
an
us
cr
ipt
9 
 
3a.1 Monotherapy 
 
3a.1.1 Lithium 
 
The first study investigating the efficacy of lithium against acute mania was 
conducted in 1971 but it did not follow a methodology which is accepted today as 
scientific standard (Stokes et al., 1971). Since then four placebo-controlled RCTs 
using modern clinical trial methodology starting in 1994 have been published.  All of 
them utilized a period of 3 weeks vs. placebo, and if a comparator was included, there 
was an extension phase without placebo (Bowden et al., 1994; Bowden et al., 2005b; 
Kushner et al., 2006; Keck et al., 2009).   
Overall there are 5 RCTs supporting the efficacy of lithium in comparison to 
placebo in acutely manic or mixed BD patients. All five are positive and the results 
are consistent. The overall response rate suggests a rough number needed to treat 
(NNT) around 5-6. The therapeutic effect appears after 7 days of treatment, that is, 
later in comparison to antipsychotics. There are limited data about the effect of 
lithium on the core symptoms of mania but there are some suggestive of an effect on 
psychotic features (Bowden et al., 2005b). Its effect specifically on mixed episodes is 
unknown and a post-hoc analysis (Swann et al., 1997) of one of these RCTs (Bowden 
et al., 1994) confirmed the efficacy of lithium only in classic manic but not mixed 
patients albeit the number of mixed patients was too small to allow firm conclusion. It 
exerts a therapeutic effect on manic-psychotic symptoms, but probably there is no 
therapeutic effect on concomitant depressive symptoms. The drop-out rate in these 
trials was comparable to placebo with probably more patients on placebo withdrawing 
from the study because of lack of efficacy while side effects were the more common 
 by guest on N
ovem
ber 17, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pt
ed
 M
an
us
cr
ipt
10 
 
reasons for withdrawal in patients taking lithium. The most common adverse events 
with lithium were nausea, vomiting, dizziness headache, insomnia, asthenia, 
constipation, diarrhoea, tremor and weight gain.  
 
3a.1.2. Antiepileptics 
 
3a.1.2.1. Valproate 
 
Limited data concerning the efficacy of valproate in acute mania exist from earlier 
studies (Emrich et al., 1980; Emrich et al., 1981; McElroy et al., 1989). The first study 
with modern methodology on the efficacy and safety of valproate in the treatment of 
acute mania, was published in 1991 (Pope et al., 1991). Since then 3 positive (Pope et 
al., 1991; Bowden et al., 1994; Bowden et al., 2006) and 2  failed RCTs (Tohen et al., 
2008b; Hirschfeld et al., 2010) were published. Another study on a heterogeneous 
sample consisting of bipolar spectrum disorder patients was negative (McElroy et al., 
2010a). A post hoc analysis of one of the RCTs (Bowden et al., 1994) did not find any 
preferential effect for divalproex in classic vs. mixed manic patients (Swann et al., 
1997). Overall the data support the usefulness of valproate against acute mania, 
although a number of issues need clarification. Its effect on psychotic symptoms is 
unknown and there seems to be no effect on concomitant depressive symptoms. The 
NNT for response is probably around 10 and the therapeutic effect is present after 5-
15 days. Although the dosages utilized in these studies were higher than those usually 
used in everyday clinical practice (15-30 mg/kg/day), they hardly achieved the target 
serum concentrations (50-100 microg/mL). The most frequent adverse events were 
somnolence, nausea, dizziness, asthenia, constipation, twitching and vomiting.  
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3a.1.2.2. Carbamazepine 
 
The earlier studies demonstrating the efficacy of carbamazepine in acute mania were 
published in the 1980s (Ballenger and Post, 1980; Post et al., 1987). Three large 
clinical trials using modern methodology have been published since 2000 all of which 
have confirmed the efficacy of carbamazepine (Weisler et al., 2004; Weisler et al., 
2005; Zhang et al., 2007). 
Thus, the data concerning the efficacy and safety of carbamazepine at dosages 400-
1600 mg/day and a mean plasma level of 8.9 microg/mL are robust. The reported 
NNT is approximately 5 for response, which starts around week 2. It is unknown 
whether carbamazepine has a beneficial effect on the core manic symptoms, in mixed 
patients or against psychotic symptoms. There seems to be a beneficial effect on 
concomitant depressive symptoms only in mixed patients but not in manic patients 
(Weisler et al., 2005). The most frequent adverse events related to carbamazepine 
treatment were dizziness, nausea, somnolence, and an increase in total cholesterol 
which was composed of increases in both high-density and low-density lipoproteins. 
 
3a.1.2.3. Other antiepileptics 
 
There is one negative (BIA-2093-203) and one fixed-dosage failed (BIA-2093-204) 
trial for eslicarbazepine (Robertson et al., 2010). Three unpublished RCTs 
(NCT00107926, NCT00107939 and NCT00099229) concerning the racemic mixture 
licarbazepine were also negative. There are two unpublished negative trials 
concerning lamotrigine in treating acute manic episodes (SCAA2008/GW609 and 
 by guest on N
ovem
ber 17, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pt
ed
 M
an
us
cr
ipt
12 
 
SCAA2009/GW610) (Goldsmith et al., 2003). Four trials concerning topiramate were 
all negative (Kushner et al., 2006). One small RCT evaluated the efficacy and safety 
of lamotrigine and gabapentin monotherapy vs. placebo in 31 patients with refractory 
bipolar and unipolar mood disorders.  Although lamotrigine differed significantly 
from placebo gabapentin did not (Frye et al., 2000). Thus the data are negative for all 
other antiepileptics except for valproic acid and carbamazepine, which suggests that 
there is no class effect concerning antiepileptics in the treatment of BD (Rosa et al., 
2009; Fountoulakis et al., 2011b). 
 
3a.1.3. Antipsychotics 
 
The earlier studies on antipsychotics supported the efficacy of  chlorpromazine 
(Klein, 1967) and suggested that antipsychotics acted more rapidly although lithium 
was more globally effective (Shopsin et al., 1975).  
 
3a.1.3.1. Haloperidol 
 
The efficacy and safety of haloperidol (up to 30 mg/day) was studied in five 
RCTs and all were positive. (McIntyre et al., 2005; Smulevich et al., 2005; Young et 
al., 2009; Vieta et al., 2010a; Katagiri et al., 2012). The results suggest a NNT 
roughly equal to 5-8 for response. The therapeutic effect is apparent as early as  day 4 
(Goikolea et al., 2013a). However it is important to note that there is a signal for the 
induction of depression in the short term (Goikolea et al., 2013b). One study reported 
no effect on the core symptoms of mania. However, although haloperidol might be 
particularly efficacious in psychotic patients, its effect on mixed patients is unknown. 
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Adverse events most commonly reported with haloperidol treatment were 
somnolence, Extrapyramidal symptoms (EPS), weight gain and constipation. 
 
3a.1.3.2. Olanzapine 
 
There are 6 positive trials supporting the efficacy of olanzapine (5-20 mg/day) 
for the treatment of manic or mixed episodes and concomitant psychotic features 
(Tohen et al., 1999; Tohen et al., 2000; Tohen et al., 2008b; McIntyre et al., 2009a, 
2010b; Katagiri et al., 2012). The NNT is approximately around 5 for response 
(defined as a 50% drop in YMRS). Olanzapine seems to have a beneficial effect on 
the core symptoms of mania, on psychotic symptoms, treats mixed patients as well as 
rapid cycling, possibly improves coexisting depressive symptoms, and response 
occurs as early as days 2-7. Olanzapine does not seem to induce a switch to 
depression. The commonest adverse events related with olanzapine treatment were 
somnolence, dizziness, dry mouth, thirst and weight gain. EPS occur but at a lower 
rate than with haloperidol. 
 
3a.1.3.3. Quetiapine 
 
There exist 4 positive studies supporting the efficacy of quetiapine up to 800 
mg/day for the treatment of acute mania (Bowden et al., 2005b; McIntyre et al., 2005; 
Vieta et al., 2010b; Cutler et al., 2011). Quetiapine does not seem to induce 
depression, on the contrary there is a clear beneficial effect on concomitant depressive 
symptoms. However, there is some doubt concerning its efficacy against mixed 
episodes (such patients were excluded in most quetiapine trials), concomitant 
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psychotic features, and in rapid cycling patients. The NNT is around 4-6 for response. 
The commonest adverse events associated with quetiapine treatment included 
sedation, dry mouth, somnolence, headache, dizziness and postural hypotension. 
 
3a.1.3.4. Aripiprazole 
 
There are 5 positive (Keck et al., 2003b; Sachs et al., 2006; Keck et al., 2009; 
Young et al., 2009; Kanba et al., 2014) and one negative fixed dosage study (El 
Mallakh et al., 2010), concerning the efficacy of aripiprazole 15-30 mg/day for the 
treatment of acute manic and mixed episodes. One study was not completed and 
reported no results . Again the effect on the core symptoms of mania is unknown. 
There is a significant effect in mixed and rapid cycling patients and it also treats 
concomitant positive psychotic features and agitation. Aripiprazole does not seem to 
induce depression but it does not seem to have any effect on concomitant depressive 
symptoms either. The NNT is approximately around 5-10 for response. Nausea, 
dyspepsia, somnolence, anxiety, vomiting, insomnia, light-headedness, constipation, 
and akathisia were the most common adverse events. There were no significant 
effects on body weight, serum prolactin or QTc prolongation.  
 
3a.1.3.5. Risperidone 
 
The efficacy of risperidone 1-6 mg/day for the treatment of acute manic and 
mixed episodes is supported by 3 positive studies (Hirschfeld et al., 2004; Khanna et 
al., 2005; Smulevich et al., 2005). The therapeutic effect is evident from day 3 
onwards. It seems also effective in the treatment of positive psychotic symptoms and 
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agitation and concomitant depressive symptoms. The NNT is approximately around 
3-5 for response. It is unknown whether risperidone has an effect on the core 
symptoms of mania or whether it is beneficial for rapid cycling patients. It does not 
seem to induce a switch to depression. Somnolence, dyspepsia, nausea and EPS were 
the most common adverse events. 
 
3a.1.3.6. Ziprasidone 
 
Three positive studies (Keck et al., 2003a; Potkin et al., 2005; Vieta et al., 
2010a) support the efficacy of ziprasidone 80-160 mg/day for the treatment of acute 
manic and mixed episodes. It has a treatment effect on the core symptoms of mania 
and on concomitant positive psychotic symptoms. It does not seem to have any 
significant effect on depressive symptoms but it also does not seem to induce a switch 
to depression. Its effect in rapid cycling patients is unknown. The NNT is 
approximately 6 for response. The commonest adverse events with ziprasidone 
treatment were EPS, somnolence, dizziness, anxiety, and dyspepsia. There were no 
significant effects on body weight or serum lipids. There was a small and clinically 
not significant QTc prolongation reported 
 
3a.1.3.7. Asenapine 
 
Three positive trials (McIntyre et al., 2009a, 2010b; Landbloom et al., 2016) 
support the efficacy of asenapine 10-20 mg/day for the treatment of acute manic and 
mixed episodes with efficacy as early as day 2. It is unknown whether it has a 
treatment effect on the core symptoms of mania, and while in one of the studies a 
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positive effect on the total Possitive and Negative Symptoms Scale (PANSS) score is 
reported, the specific effect on concomitant positive or negative psychotic features is 
unknown. Unknown is also the efficacy in rapid cycling patients. The data are 
equivocal concerning the effect on depressive symptoms but also it does not seem to 
induce depression. The NNT is between 6-12 for response. The commonest adverse 
events related with asenapine treatment were EPS, somnolence, dizziness, sedation, 
fatigue, oral hypesthesia, dry mouth, weight gain and EPS.  
 
3a.1.3.8. Paliperidone 
 
Two studies (Vieta et al., 2010b; Berwaerts et al., 2012b) provide support for 
the efficacy of 12 mg/day of paliperidone ER for the treatment of acute manic and 
mixed episodes while the data for lower dosages is conflicting. Paliperidone is 
effective as early as day 2. It is not reported whether it has a treatment effect on the 
core symptoms of mania, positive psychotic symptoms and depression and the effect 
in rapid cycling patients is unknown. It is unclear whether paliperidone ER can induce 
switches to depression. The commonest adverse events related with paliperidone ER 
treatment were headache, somnolence, EPS and prolactin elevation were the most 
common treatment-emergent adverse event.  
 
3a.1.3.9. Cariprazine 
 
Three studies (Calabrese et al., 2015; Durgam et al., 2015; Sachs et al., 2015; Durgam 
et al., 2016) confirmed the efficacy of cariprazine (3-12 mg daily) vs. placebo in the 
treatment of acute manic or mixed episodes. The NNT for response or remission is 
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approximately 4-7.  Cariprazine is reported to improve the core symptoms of mania 
but had no effect on the (Mondgomery Asberg Depression Rating Scale (MADRS). It 
improves the total PANSS but the specific effect on the PANSS positive subscale is 
unknown. Its efficacy in mixed and rapid cycling patients is unknown. 
 
3a.1.4. Other agents and treatment modalities 
 
Overall, the data for tamoxifen are positive, however, the total patient sample 
is still small (Zarate et al., 2007; Yildiz et al., 2008). One NIMH-sponsored clinical 
trial (NCT00026585) has not reported results yet. One small 3-week study was 
negative for verapamil (Janicak et al., 1998). The data concerning repetitive 
Transcranial Magnetic Stimulation (rTMS) are conflicting. There are two RCTs, one 
negative (Kaptsan et al., 2003) and one positive (Praharaj et al., 2009). 
 
3a.1.5 Summary of monotherapy trials for acute mania 
 
Overall there are sufficient data in the literature to support the general efficacy 
of a number of agents in the treatment of acute mania, however many details remain 
to be explored concerning many of the agents. Lithium, valproate, carbamazepine, 
haloperidol, olanzapine, quetiapine, aripiprazole, risperidone, ziprasidone, asenapine, 
paliperidone, cariprazine and probably tamoxifen are efficacious in the treatment of 
acute manic episodes. It should be mentioned that haloperidol probably induces 
depression. It is unsatisfactory that there are no controlled data concerning the 
usefulness of Electrocunvulsive treatment (ECT). 
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A significant problem for the everyday clinical practice is that the average 
clinician often utilizes the so-called ‘class effect’ in order to easily navigate among 
therapeutic options. However, what needs to be stressed is that while antipsychotics 
seem to possess a ‘class effect’ specific to the treatment of acute mania (possibly an 
antidopaminergic effect (Brugue and Vieta, 2007), there is no such effect in 
anticonvulsants concerning any phase of BD (Rosa et al., 2009; Fountoulakis et al., 
2011b). 
 
3a.2 Comparison of agents  
 
3a.2.1 Lithium vs. others 
 
In two studies comparing lithium with valproate, the two agents were found to 
be equivalent. There was a tendency of valproate to manifest fewer adverse events 
and dropouts but its signal for efficacy in RCTs might be driven by its effect in 
patients with mixed features (Freeman et al., 1992; Bowden et al., 1994). A similar 
finding restricting the efficacy of carbamazepine to an undefined subgroup of patients 
in contrast to a wider efficacy of lithium that was reported by another study as well   
(Lerer et al., 1987). Overall the efficacy was similar to carbamazepine but with fewer 
adverse events (Okuma et al., 1990; Small et al., 1991). There has been a comparison 
of carbamazepine with lamotrigine which should be considered to be a failed study 
(Ichim et al., 2000). It should be noted however that lamotrigine is not an effective 
antimanic agent.  
The comparison of lithium to chlorpromazine suggested that although 
chlorpromazine acts faster and might be more efficacious in more agitated patients, 
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this might be due to sedation alone, while lithium has again a broader effect on the 
core manic symptomatology (Platman, 1970; Prien et al., 1972; Shopsin et al., 1975). 
In contrast, the comparison of haloperidol and lithium suggested that haloperidol had 
a stronger and more rapid effect especially on behaviour and motor activity but 
without sedation, while lithium acted more evenly and comprehensively on the entire 
range of manic symptomatology. (Shopsin et al., 1975; Garfinkel et al., 1980).   
Lithium was found to have equal efficacy to carbamazepine (Lerer et al., 
1987; Okuma et al., 1990; Small et al., 1991), olanzapine (Berk et al., 1999; Niufan et 
al., 2008; Shafti, 2010), quetiapine (Bowden et al., 2005b; Li et al., 2008) and 
aripiprazole (Keck et al., 2009). In severely psychotic patients, it seems inferior to 
haloperidol (Shopsin et al., 1975; Garfinkel et al., 1980). Overall, lithium has a wider 
antimanic effect than valproate and carbamazepine but a weaker effect on psychotic 
symptoms and a slower onset of action in comparison to antipsychotics. Overall, 
lithium demonstrated a more favorable adverse effect profile in comparison to all 
other agents except aripiprazole and valproate. 
 
3a.2.2. Valproate vs. others 
 
In comparison to lithium, valproate was less efficacious and with a tendency 
to cause fewer adverse events and dropouts but its efficacy might be restricted to that 
specific group of patients with mixed features (Freeman et al., 1992; Bowden et al., 
1994). In one small study, it was superior to carbamazepine and had a faster onset of 
action (Vasudev et al., 2000). In another study, it was superior to oxcarbazepine but 
with more frequent adverse events (Kakkar et al., 2009). It might be less efficacious 
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in comparison to olanzapine and with a slower onset of action, but also with fewer 
adverse events (Tohen et al., 2002a; Zajecka et al., 2002; Tohen et al., 2008b).  
 
3a.2.3. Carbamazepine vs. others 
 
Carbamazepine was reported to be equally effective in comparison to lithium 
but with a higher rate of adverse events. Its efficacy appeared somewhat restricted to 
an undefined subgroup of patients in contrast to a broader spectrum of efficacy of 
lithium (Lerer et al., 1987; Okuma et al., 1990; Small et al., 1991). In another study 
carbamazepine was inferior to valproate and had a slower onset of action (Vasudev et 
al., 2000). In two other studies carbamazepine was found equal to chlorpromazine but 
with fewer adverse events (Okuma et al., 1979), and equal to haloperidol but with a 
slower onset of action (Brown et al., 1989). 
 
3a.2.4. Other antiepileptics 
 
There is one study on lamotrigine vs. lithium which should be considered as 
failed probably because it was underpowered (Ichim et al., 2000). In another one 
oxcarbazepine was found to be inferior to valproate but with fewer adverse events 
(Kakkar et al., 2009).  
 
3a.2.5. Haloperidol vs. others 
 
The comparison of haloperidol with lithium suggested that haloperidol is more 
efficacious in severely psychotic patients and exerts its effect earlier, especially on 
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behaviour and motor activity but without sedation, while lithium acted more evenly 
and comprehensively on the entire range of manic symptomatology (Shopsin et al., 
1975; Garfinkel et al., 1980). Haloperidol was found equally effective to 
carbamazepine but with a faster onset of action (Brown et al., 1989). Haloperidol had 
a faster onset of action than olanzapine but with more dropouts, and olanzapine was 
superior in the non-psychotic patients.  Both agents were equally effective in reducing 
the HDRS score in mixed patients and in patients with higher depressive scores. 
Switch to depression occurred significantly more rapidly with haloperidol than with 
olanzapine. More EPS were reported with haloperidol and more weight gain with 
olanzapine (Tohen et al., 2003b; Katagiri et al., 2012). Haloperidol was reported to be 
overall superior to quetiapine and more efficacious in psychotic patients. In contrast 
to quetiapine it had no effect on depressive symptoms. Haloperidol-treated patients 
had more dropouts and more EPS (McIntyre et al., 2005). It was reported as not 
superior to aripiprazole and did not improve the depressive symptoms measured with 
the MADRS. In comparison to aripiprazole, more haloperidol treated patients 
switched to depression, more dropped out and EPS were more frequent with 
haloperidol (Vieta et al., 2005b; Young et al., 2009).  Haloperidol was found similarly 
efficacious to risperidone (Segal et al., 1998; Smulevich et al., 2005) and superior to 
ziprasidone but also with more drop outs and adverse events (Vieta et al., 2010a). The 
comparison of 25 mg/day vs. 5 mg/day haloperidol revealed that the higher 
haloperidol dosage produced greater improvement than did the low dose but with 
more side effects (Chou et al., 1999).  
In summary, haloperidol was similar in efficacy as carbamazepine (Brown et 
al., 1989) and olanzapine (Tohen et al., 2003b; Katagiri et al., 2012), risperidone 
(Segal et al., 1998; Smulevich et al., 2005) and aripiprazole (Vieta et al., 2005b; 
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Young et al., 2009).  It was found to be superior to quetiapine (McIntyre et al., 2005) 
and  ziprasidone (Vieta et al., 2010a) and in severely psychotic patients to lithium 
(Shopsin et al., 1975; Garfinkel et al., 1980). It acted faster in comparison to lithium 
(Shopsin et al., 1975; Garfinkel et al., 1980), carbamazepine (Brown et al., 1989) and 
olanzapine (Tohen et al., 2003b; Katagiri et al., 2012). Overall it demonstrated 
superior efficacy in psychotic patients but less improvement (if any) on depressive 
symptoms. It also showed more adverse events (especially EPS), switching to 
depression and dropouts than the comparators.  
 
3a.2.6. Olanzapine vs. others 
 
Olanzapine was reported to be equally effective to lithium but with more 
adverse events, mainly weight gain (Berk et al., 1999; Niufan et al., 2008; Shafti, 
2010). It might be superior and faster acting in comparison to valproate (although this 
could be a function of dosage) but again with more adverse events (Tohen et al., 
2002a; Zajecka et al., 2002; Tohen et al., 2008b). It was found to be similar in 
efficacy to haloperidol but with a slower onset of action and fewer dropouts. The data 
suggest that during the acute phase both agents were equally effective in reducing the 
HDRS score in mixed patients and in patients with higher depressive scores. More 
EPS were registered with haloperidol and more weight gain with olanzapine (Tohen et 
al., 2003b; Katagiri et al., 2012). Olanzapine was found superior to asenapine in 
manic and mixed patients and also significantly improved the MADRS score which 
asenapine did not. Olanzapine-treated patients had more weight gain (McIntyre et al., 
2009a, 2010b).  
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Olanzapine was found to have similar efficacy as risperidone in patients 
without psychotic features, in terms of YMRS, HAM-D and MADRS change. The 
two agents were also equal in the subgroup of rapid cycling patients. Fewer 
olanzapine-treated patients dropped out of the head-to-head comparison but there was 
more weight gain in the olanzapine group (Perlis et al., 2006b). Finally an  
unpublished study of olanzapine vs. ziprasidone (NCT00329108) was stopped 
prematurely due to poor recruitment (2009). 
 
3a.2.7. Quetiapine vs. others 
 
Quetiapine is reported to be comparable to lithium but with more dropouts and 
adverse events (Bowden et al., 2005b; Li et al., 2008). Also it is reported to be inferior 
to haloperidol, with fewer dropouts and less frequent EPS, and also less efficacious in 
psychotic patients. In contrast to haloperidol it had an effect on depressive symptoms 
(McIntyre et al., 2005). 
Quetiapine is reported to be equal to paliperidone and both agents had a 
similar effect in manic and mixed patients. Body weight increase was more frequent 
in the quetiapine group, but more patients with paliperidone switched to depression 
(Vieta et al., 2010b) . 
 
3a.2.8. Other antipsychotics 
 
Chlorpromazine was found equal to pimozide with faster action probably due 
to its greater sedative effect. Sedation was the side effect most frequent with 
chlorpromazine and EPS were more frequent with pimozide (Cookson et al., 1981) 
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The following studies have already been reported and discussed above, 
however it is important to consider them again from a reverse angle. Risperidone was 
found equal to haloperidol (Segal et al., 1998; Smulevich et al., 2005) and olanzapine 
(Perlis et al., 2006b). Aripiprazole was found equal to lithium (Keck et al., 2009) and 
haloperidol (Vieta et al., 2005b; Young et al., 2009). Asenapine was found inferior to 
olanzapine (McIntyre et al., 2009a, 2010b), and paliperidone equal to quetiapine 
(Vieta et al., 2010b). There is one unpublished study comparing ziprasidone with 
olanzapine which did not report any results (2009) and another one finding it inferior 
to haloperidol (Vieta et al., 2010a). Finally there are two studies comparing 
chlorpromazine with lithium (Platman, 1970; Prien et al., 1972) and one with 
carbamazepine (Okuma et al., 1979), suggesting equal efficacy. 
 
3a.2.9. Summary of the comparison of agents  
 
Overall, comparison studies suggest that the greater the efficacy the more 
frequent the adverse events are. Although there are no sufficient data to support a big 
difference between agents, it seems that antipsychotics and lithium are more 
efficacious than valproate and carbamazepine unless a loading strategy for these 
anticonvulsants is applied. Also it seems clear that antipsychotics act earlier in 
comparison to the other compounds. The effect on depressive symptoms is unclear 
but it seems that haloperidol-treated patients might switch more often to depression.  
Earlier studies suggested that lithium could be specifically useful against the 
more ‘classic’ cases of euphoric mania, while antiepileptics might have a better 
efficacy for patients with mixed features and those with comorbidity. This is not 
supported by more recent data (Fountoulakis et al., 2012b). A factor which could have 
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affected the results is the so-called lithium-discontinuation-related refractoriness (Post 
et al., 1992) because of which patients enrolled in RCTs could constitute a sample 
more refractory to lithium treatment than expected. However, the assumption for the 
existence of lithium-discontinuation-related refractoriness is not supported by studies 
reporting that even when samples enriched for lithium refractoriness were used, no 
inferiority of lithium to the other agent was documented (Bowden et al., 1994). Also a 
recent meta-analysis of all published cases concluded that there is not sufficient data 
to support such a concept (de Vries et al., 2013). 
 
3a.3 Combination and add-on treatment 
 
Several studies examine the efficacy and safety of agents given not as 
monotherapy but combined treatments. The study samples range from patients being 
refractory to an initial treatment to drug-naive patients. In the first instance, an agent 
is used as adjunct or add-on therapy on a pre-existing treatment to which the patient 
has shown unsatisfactory response. In the second instance the study tests a 
combination treatment against monotherapy and both agents are initiated 
simultaneously. Although essentially both designs provide information on how to 
treat patients with an unsatisfactory response to monotherapy, the conclusions and the 
generalizability might differ. 
 
3a.3.1 Combination treatment 
 
Adding valproate to First Generation Antipsychotics (FGAs; haloperidol or perazine 
in this study) produced higher response rates in manic patients (70% vs. 46%) 
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compared with FGA plus placebo (Muller-Oerlinghausen et al., 2000). Similarly, 
combination of lithium (600 to 1,800 mg/day) and quetiapine XR (400 to 800 mg/day) 
was superior to quetiapine plus placebo (Bourin et al., 2014) in treating acute mania. 
Three studies that reported on combinations of mood stabilizing agents with 
haloperidol vs. haloperidol monotherapy are equivocal as the outcome depended on 
the haloperidol dosage (Garfinkel et al., 1980; Klein et al., 1984; Chou et al., 1999). 
Other studies reported on the efficacy of an antipsychotic agent and a mood stabilizer 
in comparison to mood stabilizer alone. In general, antipsychotic and carbamazepine 
combination is not superior to carbamazepine alone, primarily due to the effect of 
carbamazepine inducing the metabolism of antipsychotics in the combination group, 
thus resulting in lower plasma levels of antipsychotics. One 6-week international trial 
of olanzapine (10-30 mg/day) vs. placebo add on to carbamazepine (400-1200 
mg/day) was negative. In the olanzapine group, however, the triglyceride levels were 
significantly higher and potentially clinically significant weight gain occurred more 
frequently. Furthermore, carbamazepine significantly reduced olanzapine serum 
concentrations (Tohen et al., 2008a). Similarly, in another study, carbamazepine 
significantly reduced the serum levels of risperidone (Yatham et al., 2003) which 
contributed to the negative findings of this study on the primary efficacy measure. 
Overall the data on the combination of lithium with other agents support the 
conclusion that the combinations of lithium with haloperidol, lorazepam, 
carbamazepine, tamoxifen and allopurinol are superior to lithium alone, but not the 
combination of lithium plus ziprasidone or dipyridamole. Most of these combinations 
had more adverse events in comparison to monotherapy  (Garfinkel et al., 1980; 
Lenox et al., 1992; Small et al., 1995; Weisler et al., 2003; Bowden, 2005; Machado-
Vieira et al., 2008; Amrollahi et al., 2010). Adding allopurinol to treatment as usual 
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was not more effective compared with treatment as usual  (Weiser et al., 2014). On 
the contrary positive results were reported by the addition of 400 mg/day celecoxib on 
valproate in non-rapid cycling and non-psychotic patients (Arabzadeh et al., 2015) but 
negative when added on ECT (Kargar et al., 2015). 
A number of trials investigated the combination of an atypical antipsychotic or other 
agents with addition of an agent on top of lithium or valproate, since these two 
constituted the backbone of the treatment of bipolar disorder for decades. Overall the 
data are in support of combining lithium or valproate with asenapine, olanzapine, 
risperidone, haloperidol and tamoxifen but negative concerning gabapentin and 
medroxyprogesterone  (Pande et al., 2000; Sachs et al., 2002; Yatham et al., 2003; 
Kulkarni et al., 2006; Szegedi et al., 2012; Kulkarni et al., 2014; Xu et al., 2015b). 
The addition of folic acid to valproate has equivocal support (Behzadi et al., 2009) 
and the addition of omega-3 fatty acids has negative data (Chiu et al., 2005). Adding 
the herbal agent Free and Easy Wanderer Plus (FEWP) on carbamazepine was not 
better than carbamazepine alone but it was in comparison to placebo while 
carbamazepine monotherapy was not. Technically it does not support the use of 
FEWP in acute mania, but a number of other interpretations also exist, for example 
that adding FEWP compensates for the drop in carbamazepine levels (Zhang et al., 
2007). However that study did not define an a-priori primary outcome and therefore 
its quality is low. Finally, one study suggested that the valnoctamide plus risperidone 
combination was more effective than risperidone alone (Bersudsky et al., 2010). 
In summary, there are few but still important data suggesting that specific 
combinations are superior to monotherapy in non-refractory or otherwise selected 
samples, although it is difficult to assess the quality of many study samples. Despite 
the very small number of trials and the problems with the data quality, one could 
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generalize that the combination of an antipsychotic plus lithium or valproate is 
superior to lithium or valproate alone, with the caveat of greater side-effect burden. 
Tamoxifen and probably allopurinol are also valuable agents to use in combination 
with mood stabilizers. 
 
3a.3.2 Add-on treatment 
 
In patients refractory to haloperidol treatment, the addition of phenytoin has been 
shown to be beneficial (Mishory et al., 2000). In patients refractory to lithium, adding 
600-1200 mg/day carbamazepine or oxcarbazepine improved the outcome (Juruena et 
al., 2009) but that study was of poor quality, questionable phase of the disorder and 
outcome and without any a-priory defined primary outcome. Adding lovastatin on 
lithium was negative (Ghanizadeh et al., 2014).  
In patients refractory to lithium, valproate, or carbamazepine, it is beneficial to add 
haloperidol, olanzapine, quetiapine, aripiprazole, or asenapine (Szegedi et al., 2012)  
(Sachs et al., 2002; Tohen et al., 2002b; Sachs et al., 2004; Yatham et al., 2007; Vieta 
et al., 2008b) but not ziprasidone, topiramate, risperidone or paliperidone (Roy 
Chengappa et al., 2006; Berwaerts et al., 2011; Sachs et al., 2012b, a; Moosavi et al., 
2014). One study which used a mixed population with some patients entering after a 
minimum of 2 weeks of mood stabilizer therapy, and others starting a mood stabilizer 
and risperidone in parallel, provided inconclusive data for risperidone (Yatham et al., 
2003) as the results were likely confounded by the effects of  carbamazepine on serum 
levels of risperidone. Allopurinol was not beneficial in patients refractory to lithium, 
valproic acid, carbamazepine, or atypical antipsychotic medications (Fan et al., 2012) 
although there are some data suggesting a beneficial effect on patients refractory to 
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valproate (Jahangard et al., 2014). Adding the melatonin agonist ramelteon was also 
not efficacious in patients refractory to treatment as usual (McElroy et al., 2010b). 
There is only one sham-controlled trial of ECT as adjunctive treatment to 
chorpromazine (600 mg/day) in 30 acutely manic patients. That study supported the 
efficacy of ECT with a faster rate of improvement (Sikdar et al., 1994)  
A recent placebo-controlled 4-week RCT in 180 acutely manic patients supported the 
efficacy and safety of the purinergic agents allopurinol (600 mg/day) and 
dipyridamole (200 mg/day) as adjunctive to lithium in acute bipolar mania (Machado-
Vieira et al., 2008). Folic acid was also found to be useful as an adjunct to valproate 
in treating acute mania (Behzadi et al., 2009) There is one 5-week trial from Israel on 
32 recently admitted manic inpatients which compared valnoctamide (600-1200 
mg/day; N=15) vs. placebo (N=17) on top of risperidone (1-6 mg/day). All 
medications were started at day 1. In all efficacy measures the valnoctamide plus 
risperidone combination was more effective than risperidone plus placebo from week 
3 to week 5 Valnoctamide is an anticonvulsant analogue of valproate that does not 
undergo biotransformation to the corresponding free acid, and in mice it has been 
shown to be distinctly less teratogenic than valproate (Bersudsky et al., 2010). A pilot 
8-week study in 21 acutely manic outpatients on the usefulness of adjunctive 
ramelteon in acute mania/mixed states failed  (McElroy et al., 2010b), while another 
two on the cholinesterase inhibitor donepezil were negative (Eden Evins et al., 2006a; 
Chen et al., 2013). 
Overall, the data in partial responders or refractory patients support the addition of 
specific antipsychotics to lithium or valproate and also the use of allopurinol and the 
combination of lithium with carbamazepine or maybe oxcarbazepine.  
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3a.4 Post-hoc analyses and meta-analytic studies 
 
A very important post hoc analysis of individual patient data reported that patients 
with impaired insight (as measured with the use of item 11 of the Young Mania 
Rating Scale-YMRS) responded better; therefore treatment should be initiated 
immediately and the therapist should not wait until the patient gains sufficient insight 
(Welten et al., 2016). 
Overall, post hoc and meta-analytic studies confirm the efficacy of specific agents vs. 
placebo (Emilien et al., 1996; Yatham et al., 2004; Perlis et al., 2006a; Scherk et al., 
2007; Tamayo et al., 2010), and also confirm the superiority of antipsychotics versus 
lithium, valproate and carbamazepine both in terms of faster onset of action but also 
in terms of the overall outcome in the short-term treatment of acute mania. However, 
they also confirm that this higher efficacy comes with the cost of more frequent 
adverse events, mainly EPS, weight gain and somnolence (Correll et al., 2010; Tarr et 
al., 2010). These conclusions should be received with caution, taken into 
consideration the both the limitations of meta-analytical methods and the frequent 
conflicting results.  
Haloperidol might be the fastest acting of all (Goikolea et al., 2013a) but also the 
most likely one to induce depression (Goikolea et al., 2013b). Olanzapine was 
efficacious against mixed episodes, depressive symptoms and psychotic features as 
well as in rapid cycling patients (Baker et al., 2002; Baldessarini et al., 2003b; 
Chengappa et al., 2003; Suppes et al., 2005; Suppes et al., 2008b). Quetiapine was 
proven efficacious for all YMRS individual items, depressive symptoms and also 
against psychotic features (Vieta et al., 2005a). Risperidone vs. placebo caused higher 
remission rate and the drop-out rate because of lack of efficacy was lower, while the 
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drop-out rate because of adverse events was similar to that of placebo (Gopal et al., 
2005). Asenapine was efficacious against depressive symptoms (Szegedi et al., 2011), 
mixed episodes (Azorin et al., 2013; McIntyre et al., 2013) and has an effect on the 
core symptoms of mania (Cazorla et al., 2013). Aripiprazole had no effect in patients 
aged >55 years but was effective against psychotic symptoms (Suppes et al., 2008b; 
Fountoulakis et al., 2009a; Sayyaparaju et al., 2014). Aripiprazole, lithium and 
haloperidol overall are not efficacious against concomitant depressive features 
(Ostacher et al., 2015b). Ziprasidone was efficacious against dysphoric mania (Ketter 
et al., 2010; Stahl et al., 2010). The data of oxcarbazepine appear to be insufficient 
(Vasudev et al., 2011). A post hoc analysis of a lithium study (Bowden et al., 1994) 
confirmed the efficacy of lithium in classic manic but not mixed patients (Swann et 
al., 1997) while another post-hoc study confirmed the lack of efficacy of 
eslicarbazepine although there seems to be some signal in the secondary outcomes 
(Grunze et al., 2015). 
Meta-analytic studies also suggest that combination treatment is superior to 
monotherapy at the cost of more frequent adverse events; however, these meta-
analyses do not distinguish between add-on and combination studies and populations 
(Scherk et al., 2007; Smith et al., 2007; Tarr et al., 2011; Ogawa et al., 2014). One 
meta-analysis reported that studies outside the USA had higher effect size and the 
baseline YMRS predicted the outcome (Tarr et al., 2011) probably because of a 
mathematical structural coupling effect (Fountoulakis and Kontis, 2012). Year of 
study publication was not associated with YMRS score change. Furthermore, the 
study size, number of study sites, YMRS score required for study entry, inclusion of 
patients with mixed mania or treatment resistance, and inclusion of inpatients vs. 
outpatients had no significant influence on the outcome (Tarr et al., 2011).  
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Two recent meta-analyses attempted to rank antimanic agents according to 
efficacy. The first one utilized the method of multiple-treatments meta-analysis and 
reported that the ranking in terms of efficacy was haloperidol, risperidone, olanzapine, 
lithium, quetiapine, aripiprazole, carbamazepine, asenapine, valproate, and 
ziprasidone. According to that meta-analysis, overall, antipsychotics were 
significantly more effective than mood stabilizers, however the results of that analysis 
do not fully support such a conclusion (Cipriani et al., 2011). This meta-analysis has 
been criticized both concerning the overall methodology but also concerning the 
incomplete list of RCTs which was utilized (Fountoulakis and Siamouli, 2012). A 
more balanced meta-analysis confirmed that the response to antipsychotics was 
greater and more rapid in comparison to lithium, valproate, or carbamazepine, but it 
did not confirm any difference between haloperidol and second generation 
antipsychotics (Yildiz et al., 2010). A more recent network meta analysis did not 
support the superiority of any agent vs. another except for risperidone vs. aripiprazole 
and valproate (Yildiz et al., 2015).  
A meta-analysis which pooled data from 9 randomized, double-blind, placebo-
controlled, acute studies of ziprasidone reported that the discontinuation rate due to 
adverse events or 7% or greater weight gain between ziprasidone and placebo was not 
significant for all psychiatric conditions. In acute mania the risk for akathisia with 
ziprasidone had a Number Needed to Harm (NNH)=12, the risk for overall EPS had a 
NNH=12 and the reported-somnolence had NNH = 7 (Gao et al., 2013). Finally, a 
recent network meta-analysis reported that aripiprazole, olanzapine, quetiapine, 
risperidone, and valproate had less all-cause discontinuation rates than placebo and 
that there is a similar efficacy profile for haloperidol, second-generation 
antipsychotics, and mood stabilizers (Yildiz et al., 2014) while a meta-analysis of 
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combination studies confirmed the higher rate of adverse events in comparison to 
monotherapy (Galling et al., 2015). 
The analysis of the data concerning the usefulness of the cholinesterase inhibitors 
galantamine and donepezil as well as the glutamate receptor antagonist memantine 
was negative (Veronese et al., 2016). 
 
3b. Acute bipolar depression  
 
Bipolar depression is not well studied, and the common practice among clinicians is 
to extrapolate the clinical data and wisdom from the treatment of unipolar to bipolar 
depression. However, the clinical trials that examined the efficacy of various agents 
have raised questions about the validity of such strategy.  
The agents are listed below in a ‘historical’ sequence with lithium and anticonvulsants 
first, then antidepressants and finally with antipsychotics on the basis of the year of 
the first study they were investigated.  
The data on monotherapy and combination treatment for acute bipolar depression and 
its special characteristics are shown in table 3.  
 
 
3b.1 Monotherapy 
 
3b.1.1. Lithium 
 
The earlier studies on the efficacy of lithium against bipolar depression provided 
some positive data but are difficult to interpret (Goodwin et al., 1969; Greenspan et 
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al., 1970; Stokes et al., 1971; Goodwin et al., 1972; Noyes and Dempsey, 1974; 
Noyes et al., 1974; Baron et al., 1975; Mendels, 1976; Donnelly et al., 1978; 
Srisurapanont et al., 1995). There is only one modern and rigorously conducted RCT 
(EMBOLDEN I) and it was negative for lithium while it was positive for quetiapine. 
While in this particular study the mean lithium serum levels were 0.61 mEq/lt, with 
34.9% of patients having levels below 0.6 mEq/lt, a post-hoc analysis reported that 
the results were negative also in patients with lithium levels >0.8 mEq/lt and also in 
patients who completed the study. Furthermore, lithium level did not correlate with 
change in depression rating scores (Young et al., 2010).   
 
3b.1.2. Antiepileptics 
 
3b.1.2.1. Valproate 
 
There are three small positive trials (Davis et al., 2005; Ghaemi et al., 2007; Muzina 
et al., 2010) and one failed (Sachs et al., 2001) which is not published and can be 
assessed only through two meta-analytic papers (Bond et al., 2010; Smith et al., 
2010). Taken together, these studies suggest that there are some data (though 
somewhat inconsistent and not sufficient), coming from small trials supporting the 
efficacy of valproate (titrated up to 2500 mg/day) in bipolar depression, especially in 
BD-I patients and on the core symptoms of depression. There is possibly some 
efficacy against concomitant anxiety. 
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3b.1.2.2. Carbamazepine 
 
The old small withdrawal study concerning carbamazepine efficacy against bipolar 
depression were positive (Ballenger and Post, 1980; Post et al., 1983; Post et al., 
1986) but also suggested that plasma levels do not correlate with the treatment effect 
(Post et al., 1983). A more recent 12-week double-blind, randomized, placebo-
controlled study from China had equivocal results (Zhang et al., 2007). 
 
3b.1.2.3. Lamotrigine 
 
There are five trials which investigate the efficacy and safety of lamotrigine in the 
treatment of acute bipolar depression (SCA100223/NCT00274677, 
SCA30924/NCT00056277, SCA40910, SCAA2010 and SCAB2001). One included 
BD-II patients alone and one a mixed population of BD-I and BD-II patients. All were 
negative concerning the primary outcome (Calabrese et al., 1999; Goldsmith et al., 
2003; Ostacher et al., 2008) although in one study lamotrigine separated from placebo 
on MADRS, an important secondary outcome measure (Calabrese et al., 1999). A 
small double-blind, randomized study with crossover series of three 6-week 
monotherapy evaluations, in a mixed unipolar-bipolar population reported that 
lamotrigine was superior to placebo (Frye et al., 2000). Overall the data are negative 
concerning the efficacy of lamotrigine in acute bipolar depression although the 
presence of a weak signal cannot be ruled out. 
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3b.1.3. Antidepressant monotherapy 
 
Despite the fact that antidepressants have established efficacy in unipolar depression, 
which defines them as a class of drugs which includes different kinds of molecules, 
such a ‘class effect’ does not appear to be present for bipolar depression 
(Fountoulakis et al., 2011b). Although the data are problematic, the use of 
antidepressants is neither encouraged nor prohibited by all treatment algorithms, 
which however consistently advise the concomitant use of an antimanic agent. The 
current view is that antidepressant monotherapy should not be used in bipolar 
depression (Vieta, 2014). Older placebo-controlled studies were mostly positive but 
difficult to judge on the basis of modern criteria and understanding of methodology.  
An early study reported superiority of tranylcypromine vs. placebo in anergically 
depressed patients and suggested that tranylcypromine could be efficacious against 
bipolar depression since anergic depression most typically occurs in BD and in 
pseudounipolar affective illnesses (Himmelhoch et al., 1982). However the 
methodology of this study has been criticised.  
The first trial reported that fluoxetine and imipramine were efficacious vs. placebo but 
the interpretation of the results of this study is complicated by the concomitant use of 
lithium, especially in the fluoxetine group (Cohn et al., 1989). A second small trial 
was negative for fluoxetine and olanzapine monotherapy and also for the olanzapine-
fluoxetine combination (OFC) (Amsterdam and Shults, 2005a). Another small 
placebo-controlled, cross-over study lasting 9 months on 10 BD-II depressed patients 
suggested that escitalopram might be better than placebo as monotherapy for 
depression and without worsening of illness course (Parker et al., 2006). The only 
properly conducted study on a sample of adequate size was an international trial on 
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740 patients with bipolar depression (both BD-I and BD-II). This study was negative 
for paroxetine 20 mg/day while it was positive for quetiapine. However, paroxetine 
produced a significant improvement in anxiety in terms of change of HAM-A scale 
score from baseline but was not efficacious concerning depressive symptoms in any 
subgroup of patients. The most frequent adverse events were dry mouth, sedation, 
headache, insomnia, and nausea with paroxetine treatment (McElroy et al., 2010c). 
In conclusion, given that the efficacy data are conflicting along with concerns about 
manic/hypomanic switch, the use of antidepressant monotherapy is strongly 
discouraged. 
 
3b.1.4. Antipsychotics 
 
3b.1.4.1. Olanzapine 
 
An international trial supported the superiority of olanzapine (5-20 mg/day) vs. 
placebo in the treatment of bipolar depression. However olanzapine monotherapy was 
proven inferior to OFC and furthermore, the analysis of individual MADRS items 
suggested that in contrast with OFC, olanzapine monotherapy had no effect on the 
core symptoms of depression (Tohen et al., 2003c). Also, a further small study was 
underpowered and negative  (Amsterdam and Shults, 2005a). Another small study 
was positive (Wang et al., 2014). It is important to note mind that in order to 
demonstrate a true antidepressive effect, an effect on the ‘core items’ of depression 
should be demonstrated (Bech, 2001; Lecrubier and Bech, 2007). To answer this 
question, another trial was conducted and the results again suggested that olanzapine 
(5-20 mg/day) was superior to placebo but again no effect of olanzapine was observed 
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on the ‘core’ depressive symptoms according to LOCF analysis but surprisingly 
MMRM analysis showed a significant effect on core symptoms (Tohen et al., 2012). 
Overall, while olanzapine separated from placebo in two large clinical trials, of 
bipolar depression, the data concerning its efficacy on the core symptoms of 
depression are equivocal. 
 
3b.1.4.2. Quetiapine 
 
Overall, there are 6 studies concerning the efficacy of quetiapine in bipolar 
depression. All of them were positive. Quetiapine IR or XR is reported to be 
efficacious at dosages of both 300 and 600 mg/day. It is important to note that 
quetiapine had a similar efficacy in BD-I and BD-II patients as well as in rapid 
cycling, and it significantly improved all the MADRS items corresponding to the core 
symptoms of depression and also improved concomitant anxiety (Calabrese et al., 
2005b; Thase et al., 2006; McElroy et al., 2010c; Suppes et al., 2010; Young et al., 
2010; Li et al., 2016) 
 
3b.1.4.3. Aripiprazole 
 
Two identically designed, 8-week, multicentre, randomized, double-blind, placebo-
controlled studies (CN138-096 and CN138-146) to evaluate the efficacy and safety of 
aripiprazole monotherapy in depressed BD-I outpatients without psychotic features 
were both negative for aripiprazole (Thase et al., 2008). It has been argued that the 
failure of these two trials was due to the ‘catching up’ of the placebo group after week 
6 rather than because of a lack of efficacy of aripiprazole, however, at endpoint the 
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placebo response in terms of MADRS score change in the aripiprazole studies (-10.6 
and -11.5) was similar to what was observed also in the quetiapine studies (from -10.3 
to -11.9) while the aripiprazole response (-11.9 and -12.3) was clearly lower to the 
response observed with quetiapine (from -15.4 to -17.4). Another confounding factor 
in these studies was that transient use of hypnotics was permitted but not after 4 
weeks into the trial. 
 
3b.1.4.4. Ziprasidone 
 
There are two negative trials (NCT00141271 and (NCT00282464) concerning 
ziprasidone, which were published in a single paper (Lombardo et al., 2012). The 
placebo responses in these trials were over 50% which might have contributed to 
negative results. One trial of ziprasidone in bipolar spectrum depressed patients was 
negative (Patkar et al., 2015). 
 
3b.1.4.5. Lurasidone 
 
One 6-week trial in bipolar depressed patients without psychotic features reported that 
lurasidone (20-60 mg/day or 80-120 mg/day) was superior to placebo.  Lurasidone 
had an effect on the core symptoms of depression. Both lurasidone groups also 
experienced significant improvements compared with placebo in anxiety symptoms 
and in patient-reported measures of quality of life and functional impairment (Loebel 
et al., 2014a). As this was a 6-week study, and having in mind the negative findings at 
endpoint (week 8) for aripiprazole while the data was positive at week 6, one might be 
cautious concerning the interpretation of the lurasidone data. However, the magnitude 
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of improvement and the absolute values of lurasidone and placebo-induced change in 
the MADRS score argue in favor of lurasidone. 
 
3b.1.4.6. Other agents and treatment options 
 
There is a small number of early studies on very small samples concerning the α2-
adrenergic agonist clonidine, the α2-adrenergic antagonist idaxozan and Thyrotropin-
releasing hormone (TRH) (Kastin et al., 1972; Jimerson et al., 1980; Osman et al., 
1989). A trial concerning the usefulness of ECT has been announced (Kessler et al., 
2010) but its results have not been published until now. Three other uncontrolled trials 
suggested that bipolar depressives respond to ECT and conflicting results exist as to 
whether unipolar or bipolar depression respond better although probably to a lesser 
extent in comparison to unipolars (Daly et al., 2001; Medda et al., 2009; Bailine et al., 
2010). A recent study showed ECT to be superior to a pharmacotherapy algorithm 
(Schoeyen et al., 2015). There is one negative study rTMS (Nahas et al., 2003). There 
is a small positive study on the usefulness of Cranial Electrotherapy Stimulation in 
BD-II Depression (McClure et al., 2015). 
 
3b.2.2. Comparison of treatment options 
 
Since only a limited number of options for the treatment of bipolar depression exist, 
comparison studies are limited and often they compare agents with unproven efficacy. 
Some early studies were too small and are problematic concerning their methodology 
(Coppen et al., 1972; Kessell and Holt, 1975; Aberg-Wistedt, 1982). Overall the 
comparison data are sparse and they suggest antidepressants are equal in efficacy but 
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with a different adverse events profile (Baumhackl et al., 1989; Cohn et al., 1989; 
Himmelhoch et al., 1991; Grossman et al., 1999; Amsterdam and Garcia-Espana, 
2000; Silverstone, 2001; Vieta et al., 2002). Clomipramine might be more efficacious 
than imipramine in refractory BD depressed patients (Thase et al., 1992). 
However the efficacy of antidepressants should be considered in combination with the 
negative monotherapy data for paroxetine. The frequent use of concomitant mood 
stabilizers as ‘background’ medication complicates the interpretation of results. OFC 
is superior to olanzapine alone (Tohen et al., 2003c) and to lamotrigine (Brown et al., 
2006) and has an effect on the core symptoms of depression. The comparison of 
paroxetine with venlafaxine suggests a higher switching risk for patients treated with 
venlafaxine (Vieta et al., 2002). The relatively higher risk of treatment emergent 
affective switches with venlafaxine compared to sertraline or bupropion has also been 
reported (Post et al., 2006). However, a more recent study reported that venlafaxine 
was equal to lithium and without any increase in the switch rate (Lorenzo-Luaces et 
al., 2016). 
 
3b.2.3. Combination and add-on treatment  
 
3b.2.3.1 Combination treatment 
 
There is one trial on BD-I depressed patients which suggested that the OFC (6 and 25, 
6 and 50, or 12 and 50 mg/day) was superior both to olanzapine monotherapy and to 
placebo. The OFC arm was relatively small (only 86 patients) and this was one of the 
limitations of the study. The analysis of individual MADRS items suggested that OFC 
had an effect on the core symptoms of depression. In comparison to placebo and 
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olanzapine, the OFC arm also had a lower number of inpatients, less frequent 
psychotic features, more rapid cycling (which may translate in higher rates of 
‘spontaneous remission’) and lower number of centres. All these could translate into 
better response and limit interpretation (Tohen et al., 2003c). Another small study was 
negative but also underpowered to detect any treatment effect  (Amsterdam and 
Shults, 2005a). A second study from the US (STEP-BD), utilized a combination 
treatment by adding paroxetine or bupropion or placebo to a mood stabilizer. The 
results suggested that the two antidepressant arms did not perform significantly better 
than placebo on top of a mood stabilizer after 26 weeks in terms of recovery rates or 
transient remission. The switch rates were similar as was the drop-out rate (Sachs et 
al., 2007) and neither response to treatment nor switching were dose dependent (Tada 
et al., 2015). The third trial was a 12-week double-blind, randomized, placebo-
controlled study from China which reported that carbamazepine plus the herbal 
FEWP (36 g/day) was superior to carbamazepine alone and to placebo, but the quality 
of this study is considered to be low because there was no a-priori defined primary 
outcome (Zhang et al., 2007). 
In a small study, 21 patients with acute BD-II depression, being on therapeutic levels 
of lithium or valproate, were randomly assigned to treatment with the dopamine 
D2/D3 antagonist pramipexole (N=10) or placebo (n=11) for 6 weeks. All subjects 
except for one in each group completed the study. There was a superiority of 
pramipexole in terms of response (60% vs. 9%; p=0.02). One subject on pramipexole 
and two on placebo developed hypomanic symptoms (Zarate et al., 2004). Another 
small study randomized 17 BD depressed patients to receive adjunctive inositol or 
placebo for 6 weeks on lithium or valproate. The results were numerically in favor of 
inositol in terms of response rates (44% vs. 0%; p=0.053) (Eden Evins et al., 2006b).  
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3b.2.3.2 Add-on treatment 
 
Overall, the data suggest that in bipolar depressed patients who experience depression 
while under lithium treatment, it is appropriate to add lamotrigine (van der Loos et al., 
2009; van der Loos et al., 2010, 2011), the D2 antagonist L-sulpiride (Bocchetta et al., 
1993) or maybe oxcarbazepine (Juruena et al., 2009) but not imipramine (Nemeroff et 
al., 2001). The data on adding paroxetine and amitriptyline are equivocal (Bocchetta 
et al., 1993; Bauer et al., 1999a; Pilhatsch et al., 2010; van der Loos et al., 2010). 
Imipramine and venlafaxine might pose the patients at an increased risk of switching 
to the opposite pole without any visible therapeutic benefit in comparison to other 
antidepressants (Nemeroff et al., 2001; Vieta et al., 2002)   
In BD patients experiencing depression during treatment with lithium or valproate, 
ketamine or lurasidone could be added. Lurasidone also improves anxiety and 
ketamine improves suicidality in these patients. Response to a single ketamine 
infusion appears within minutes but does not last more than 3-4 days (Young et al., 
2000; Diazgranados et al., 2010; Zarate et al., 2012; Loebel et al., 2014b; Xu et al., 
2015a). However there is one unpublished failed study with lurasidone as add-on to 
lithum or valproate (Suppes et al., 2013; Sanford and Dhillon, 2015). 
A small placebo-controlled adjunctive study of aripiprazole to lithium and citalopram 
was negative. However the study was underpowered and the study sample was too 
small to detect any differences (Quante et al., 2010). 
The data on the options to treat BD patients who experience a depressed episode 
during treatment with mood stabilizers suggest that it is not appropriate to add 
ziprasidone (Sachs et al., 2011) and the data are also negative also concerning bipolar 
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spectrum depressed patients (Patkar et al., 2015). The antiepileptic agent topiramate 
and levitiracetam should be avoided because there is a risk of worsening depression 
and inducing suicidality (Fountoulakis et al., 2012c; Siamouli et al., 2014; 
Fountoulakis et al., 2015). Imipramine and venlafaxine increased the risk of switching 
to the opposite pole without any visible therapeutic benefits in comparison to other 
antidepressants (Sachs et al., 1994; Post et al., 2001; Shelton and Stahl, 2004; Post et 
al., 2006; Schaffer et al., 2006; Altshuler et al., 2009; Saricicek et al., 2010; Sachs et 
al., 2011). 
The data are negative concerning the addition of memantine to lamotrigine (Anand et 
al., 2012) or valproate (Lee et al., 2014b; Lee et al., 2014a), ketamine to ECT 
(Abdallah et al., 2012), lisdexamfetamine to treatment as usual (McElroy et al., 2015) 
and the melatonergic antidepressant agomelatine to lithium or valproate (Yatham et 
al., 2016). 
Another placebo-controlled study in 85 bipolar depressive patients with adjunctive 
modafinil (a wake-promoting agent; mean dose 177 mg/day) demonstrated improved 
outcomes of bipolar depression without switching to mania or hypomania.  Both the 
response and remission rates were significantly higher in the modafinil group (44% 
and 39%) compared with the placebo group (23% and 18%) (Frye et al., 2007). 
Although that study did not report a higher risk for manic switches, it has been 
reported that modafinil could cause subclinical switches (Fountoulakis et al., 2008c). 
One published study for the treatment of acute BD-I depression with adjunct 
armodafinil (the longer lasting isomer of modafinil; dosage 150 mg/day; N=128)) on 
lithium, valproate or olanzapine was positive (Calabrese et al., 2010; Calabrese et al., 
2014). However two other studies were reported to be negative (Ostacher, 2014; 
Ketter et al., 2015). One small study on the efficacy of the antidiabetic agent 
 by guest on N
ovem
ber 17, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pt
ed
 M
an
us
cr
ipt
45 
 
pioglitazone as add-on to lithium in bipolar patients without diabetes mellitus was 
positive (Zeinoddini et al., 2015). A trial of celecoxib (400 mg/day) did not support its 
efficacy as an adjunct in the treatment of depressive or mixed episodes (Nery et al., 
2008). One study with add-on pregnenolone (titrated to 500 mg/day) was negative 
(Brown et al., 2014) while a very small placebo controlled trial without an a-priori 
defined primary outcome suggested that adding supraphysiologic doses of 
levothyroxine (L-T4) to a mood stabilizer improves the outcome (Bauer et al., 2016). 
Some data support the usefulness of omega-3 fatty acids as adjunctive therapy in 
bipolar depression but not mania but the data are conflicting and inconclusive  (Stoll 
et al., 1999; Chiu et al., 2005; Frangou et al., 2006; Keck et al., 2006b; Frangou et al., 
2007; Murphy et al., 2012; Sarris et al., 2012; Sylvia et al., 2013) 
Although there is a wide consensus on the usefulness of ECT both against acute 
mania and acute bipolar depression and in refractory cases, controlled hard data are 
scant (Loo et al., 2010). A recent study suggests that ECT may be more effective than 
pharmacotherapy for treatment-resistant bipolar depression (Schoeyen et al., 2015). 
Another potential tool could be TMS, however it has been poorly investigated in 
bipolar depression (Dell'Osso et al., 2009). Sleep deprivation and other noninvasive 
circadian-related interventions could be useful add-on treatments in order to 
accelerate and sustain the antidepressant response (Wu et al., 2009). One study on 
bright light therapy in bipolar depression was negative (Dauphinais et al., 2012). 
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3b.4 Post-hoc, review and meta- analytic studies 
 
3b.4.1 Post-hoc analyses of controlled trials 
 
A post hoc analysis of the OFC and olanzapine data (Tohen et al., 2003c) reported 
patients with bipolar depression receiving olanzapine or OFC had greater 
improvement in health-related quality of life than those receiving placebo, and 
additionally OFC treatment is superior to olanzapine alone (Shi et al., 2004b). A 
second post hoc analysis of the same data set data reported that the beneficial effect 
was already present at day 7. A number of alternative methods of analysis of the data 
(pattern analysis, survival analysis and mixed-effects regression analysis) confirmed 
the superiority of both olanzapine and OFC vs. placebo (Dube et al., 2007). A sub 
analysis of Japanese subpopulation from the second olanzapine study (Tohen et al., 
2012) further supported the efficacy of olanzapine in the treatment of bipolar 
depression (Katagiri et al., 2013). A pooled analysis of the two olanzapine studies 
(Tohen et al., 2003c; Tohen et al., 2012) which utilized Last Observation Carried 
Forward (LOCF) data supported the efficacy of olanzapine on the core depressive 
items (Tohen et al., 2013). 
One post-hoc analysis included two quetiapine trials (Calabrese et al., 2005b; Thase et 
al., 2006) and confirmed the efficacy of quetiapine as monotherapy, in comparison to 
placebo, for the treatment of acute depressive episodes in BD-II disorder (Suppes et 
al., 2008a). Another post hoc analysis of only one of these trials (Calabrese et al., 
2005b) concluded that quetiapine significantly improved quality of life from week 4 
onwards as well as quality of sleep (Endicott et al., 2007). A further post hoc analysis 
of the same study reported that the NNT was 5 for both response and remission for 
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quetiapine (600 and 300 mg/day) compared with placebo (Cookson et al., 2007). 
Another post-hoc analysis of these two quetiapine trials reported that quetiapine was 
effective in BD-I depressed patients already from week 1 onwards (Weisler et al., 
2008). 
One post-hoc analysis of pooled data from two similarly designed trials who assessed 
the impact of aripiprazole monotherapy (Thase et al., 2008) reported that at endpoint 
aripiprazole was not efficacious in the more severely depressed patients (Thase et al., 
2012). The post-hoc analysis of the two negative unpublished ziprasidone 
monotherapy trials confirmed that ziprasidone did not show superiority over placebo 
at week 6 in the treatment of bipolar depression and was not efficacious in the more or 
less severely depressed patients (Lombardo et al., 2012). 
A post-hoc analysis of a 6-weeks trial of imipramine, phenelzine or placebo reported 
that BD-II depressive patients respond in a similar way to unipolar patients (Agosti 
and Stewart, 2007). 
An interesting post-hoc analysis of the lurasidone studies developed a mathematical 
model for the drug and placebo responses and trajectories (Chapel et al., 2016) while 
a meta-analysis of combination studies confirmed the higher rate of adverse events in 
comparison to monotherapy (Galling et al., 2015). A third analysis suggested a 
beneficial effect of lurasidone on functioning which was partially mediated through 
the improvement of depressive symptoms and partially a direct effect (Rajagopalan et 
al., 2016). 
The meta-analysis of ketamine studies support its efficacy but suggest but the data are 
conflicting as to whether the therapeutic effect extends beyond day 4 and up to day 7 
(Lee et al., 2015; Romeo et al., 2015). 
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3b.4.2 Review and Meta-analytic studies 
 
A review confirmed that lamotrigine had only negative data concerning the primary 
outcome in acute bipolar depression (Amann et al., 2010), however there was some 
kind of positive signal in some of the secondary outcomes. The pooling of raw data 
from the lamotrigine studies found a significant effect in terms of response (HAM-D 
score, RR=1.27, 95% CI 1.09-1.47, p=0.002) and remission rates (MADRS score, 
RR=1.21, 95% CI 1.03–1.42, p=0.021). There was a significant change in the 
MADRS total score from baseline (p=0.04) but not in the HAM-D (p=0.08). Baseline 
severity of depression seemed to play a significant role and lamotrigine was superior 
to placebo in patients with HAM-D score >24 (RR=1.47, p=0.001) but not in those 
with HAM-D score < or =24 (RR=1.07, p=0.445). This meta-analysis reported an 
admixture of contradictory results, with lamotrigine being efficacious according to 
one outcome but not according to another (e.g. according to MADRS but not to 
HAM-D and vice versa). Also the interaction by severity was because of a higher 
response rate in the placebo group in the moderately ill patients, while the response 
rate to lamotrigine was independent of severity (Geddes et al., 2009). The efficacy of 
carbamazepine was supported by two other reviews (Srisurapanont et al., 1995; 
Yatham et al., 1997). 
A number of meta-analyses which were published later, reported that only quetiapine, 
OFC, lurasidone and to a lesser extend olanzapine monotherapy exert efficacy in the 
treatment of bipolar depression. They also reported negative results for lamotrigine 
and aripiprazole, lithium as well as for adjunctive inositol (Cruz et al., 2010; Kemp et 
al., 2010; Tamayo et al., 2010; Vieta et al., 2010c; De Fruyt et al., 2011; Gao et al., 
2011; De Fruyt et al., 2012; Silva et al., 2013; Citrome et al., 2014; Mukai et al., 
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2014; Suttajit et al., 2014). Also, it was reported that patients who do not respond in 
the first two weeks of treatment are unlikely to respond eventually and would benefit 
from a change in treatment (Kemp et al., 2010). 
Two meta-analyses using identical studies suggested there is some weak efficacy for 
valproate (Bond et al., 2010; Smith et al., 2010) and one suggested the same for 
aripiprazole (Fountoulakis et al., 2011a). Another one suggested that treatment with 
ziprasidone increases the risk for akathisia and reported somnolence which seemed to 
be dose-dependent (Gao et al., 2013). There are three meta-analysis with conflicting 
conclusions concerning the efficacy of antidepressants (Gijsman et al., 2004; Sidor 
and Macqueen, 2010, 2012; Vazquez et al., 2013) However, it is clear that a class 
effect is not present concerning antidepressants in bipolar depression (Fountoulakis et 
al., 2011b). Another meta-analysis suggested that mood stabilizer monotherapy is 
efficacious but the addition of an antidepressant does not increase efficacy (Van 
Lieshout and MacQueen, 2010).  
One meta-analysis which focused on depressed patients with BD-II reported that   
quetiapine had compelling evidence supporting its efficacy, while there was some 
support for the efficacy of lithium, antidepressants, and pramipexole. The data for 
lamotrigine were equivocal (Swartz and Thase, 2011), while some data suggest the 
efficacy of stimulants, especially modafinil (Corp et al., 2014), ketamine (Fond et al., 
2014; McGirr et al., 2014), and anti-inflammatory agents compared with conventional 
therapy alone in the treatment of bipolar depression (Rosenblat et al., 2016).  
Two reviews investigated the issue of the treatment of refractory bipolar depression 
and concluded that the available hard data is extremely scarce and most of the 
strategies remain essentially experimental, however there seem to be some which are 
potentially efficacious and promising (Aan Het Rot et al., 2012; Sienaert et al., 2013). 
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One meta-analysis compared the efficacy of ECT in unipolar vs. bipolar depression 
and identified 6 relevant studies. It reported a similar rate of response in both 
disorders (50.9% vs. 53.2%) (Dierckx et al., 2012). 
Finally a meta-analysis reported that the probability of receiving placebo, baseline 
illness severity, and trial duration, correlate with placebo response rates and/or 
clinical trial outcome in RCTs of pharmacotherapy for bipolar depression (Nierenberg 
et al., 2015), while another one was negative concerning the usefulness of 
galantamine, donepezil and memantine (Veronese et al., 2016). 
 
 
3c. Maintenance treatment 
 
The efficacy data for monotherapy for the maintenance treatment phase are shown in 
table 4. The data concerning the combination treatment are shown in table 5 
 
3c.1. Monotherapy  
 
3c.1.1 Lithium 
 
There are a number of historic small studies which investigated the usefulness of 
lithium in the maintenance treatment of BD (Baastrup et al., 1970; Melia, 1970; Small 
et al., 1971; Cundall et al., 1972; Hullin et al., 1972; Persson, 1972; Prien et al., 
1973b; Prien et al., 1973a; Dunner et al., 1976; Fieve et al., 1976; Fyro and Petterson, 
1977; Klein et al., 1981; Christodoulou and Lykouras, 1982; Kane et al., 1982; Margo 
and McMahon, 1982; Mander and Loudon, 1988; Post et al., 1992). All of them 
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reported positive findings; however, a number of drawbacks including the obsolete 
methodological approach and the utilization of mixed and small samples make the 
results of these trials difficult to interpret.  
Overall there are four randomized placebo controlled studies concerning the efficacy 
of lithium in the maintenance treatment of BD. One is negative/failed (Bowden et al., 
2000) and three are positive (Bowden et al., 2003; Calabrese et al., 2003b; Weisler et 
al., 2011). The fourth is a small discontinuation study (Kafantaris et al., 2004). Two of 
the positive studies support the usefulness of lithium in the prevention of manic but 
not depressive episodes irrespective of the polarity of the index episodes (Bowden et 
al., 2003; Calabrese et al., 2003b). The third study also supports its usefulness in the 
prevention of depressive episodes (Weisler et al., 2011). There are no data on the 
efficacy concerning the prevention of mixed episodes or for rapid cycling patients. It 
is important to note that the study samples were not enriched for response to lithium. 
On the contrary, one study had a sample enriched for response to quetiapine (Weisler 
et al., 2011), while two others had samples enriched for lamotrigine (Bowden et al., 
2003; Calabrese et al., 2003b) which, however, is not efficacious against acute mania. 
There are some problems with the design of the studies, especially concerning the 
magnitude of improvement during the acute treatment phase and the duration the 
patients were required to be stable before entering the double-blind phase. With a few 
exceptions, most are essentially relapse prevention, not maintenance studies. 
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3c.1.2. Antiepileptics  
 
3c.1.2.1. Valproate 
 
As mentioned above, there is one properly conducted trial (Bowden et al., 2000) in 
which valproate was the agent under investigation. Lithium served as active control, 
and since, as shown above, lithium has proven efficacy during the maintenance phase 
of BD, this specific trial is best considered to be a failed study and not negative for 
valproate. 
 
3c.1.2.2. Carbamazepine 
 
Concerning carbamazepine, there is only one small placebo controlled study. 
Although carbamazepine was effective in 60% of cases relative to 22% in the placebo 
group, the differences were not significant likely due to lack of power. Further, there 
were methodological issues with the study  design and hence, the data are difficult to 
interpret (Okuma et al., 1981). 
 
3c.1.2.3. Lamotrigine  
 
Overall there are three placebo controlled RCTs concerning the efficacy of 
lamotrigine in the maintenance treatment of BD. Two of them suggest lamotrigine is 
efficacious in the prevention of depressive but not manic episodes irrespective of the 
polarity of the index episodes (Bowden et al., 2003; Calabrese et al., 2003b). There 
are no data concerning index mixed episodes. The only study in rapid cycling patients 
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was negative concerning the primary outcome (Calabrese et al., 2000). All studies 
were enriched for tolerability to lamotrigine, but one should have in mind that 
lamotrigine is neither efficacious against acute mania nor acute bipolar depression. 
There were some problems with the design of the studies, particularly concerning the 
magnitude of improvement during the acute treatment phase and the duration the 
patients were stable before entering the double-blind phase. Essentially they were 
relapse prevention, not maintenance studies. 
 
3c.1.3 Antidepressants 
 
There are 2 small old negative studies concerning the efficacy of imipramine (Prien et 
al., 1973a; Kane et al., 1982), while on the contrary, 3 other small studies in BD-II 
patients provide some support for the usefulness of fluoxetine monotherapy in the 
prevention of depressive episodes (Amsterdam et al., 1998; Amsterdam and Shults, 
2005b, 2010).  
 
3c.1.4 Antipsychotics 
 
3c.1.4.1 Olanzapine 
 
Three trials provide support for the efficacy of olanzapine in the prevention of manic, 
depressive or mixed episodes in patients with an index manic or mixed episode which 
responded to olanzapine treatment during the acute phase (Tohen et al., 2006; 
Berwaerts et al., 2012a; Vieta et al., 2012). There is some data to support the notion 
that the efficacy of olanzapine is not restricted to those patients who responded to 
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olanzapine during the acute phase. Its long-term effects in rapid cycling patients are 
unknown. 
 
3c.1.4.2 Aripiprazole 
 
There are two trials which support the efficacy of aripiprazole in the prevention of 
manic but not depressive episodes in BD patients after an index manic or mixed 
episode who responded to aripiprazole during the acute phase (Keck et al., 2006a; 
Keck et al., 2007).  These two trials utilize a methodology which satisfies stringent 
criteria concerning the definition of ‘maintenance’ treatment. 
 
3c.1.4.3 Quetiapine 
 
There is one published positive study which investigated the efficacy and safety of 
quetiapine IR monotherapy (300-800 mg/day) as maintenance treatment in BD-I 
patients compared with switching to placebo or lithium. The time to recurrence of any 
mood event was significantly longer for both quetiapine and lithium vs. placebo. Both 
quetiapine and lithium significantly increased time to recurrence of both manic and 
depressive episodes compared with placebo (Weisler et al., 2011). A second study in 
patients who had recovered from bipolar depression reported that quetiapine 
prevented depressive but not manic episodes (Young et al., 2014). 
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3c.1.4.4 Paliperidone 
 
There is one positive study which supports the usefulness of paliperidone in the 
prevention of manic but not depressive recurrences in patients with index manic or 
mixed episodes who responded to paliperidone during the acute phase (Berwaerts et 
al., 2012a).  
 
3c.1.4.5 Risperidone long-acting injectable (RLAI) 
 
Two studies support the efficacy of RLAI in the prevention of manic but not 
depressive episodes in BD-I patients with a manic or mixed index episode who 
responded to oral risperidone or RLAI during the acute phase (Quiroz et al., 2010; 
Vieta et al., 2012).  
 
3c.1.5 Conclusion of monotherapy trials 
 
Lithium, olanzapine, quetiapine, aripiprazole, paliperidone and RLAI are efficacious 
in the prevention of manic episodes in patients who recovered from an index manic or 
mixed episode. Olanzapine and quetiapine are also efficacious in the prevention of 
depressive episodes. Quetiapine was efficacious irrespective of the index episode. 
Olanzapine was also efficacious in the prevention of mixed episodes. There is a lack 
of data concerning carbamazepine or valproate.  
Lamotrigine is efficacious in the prevention of depressive but not manic episodes 
irrespective of index episode. It was not efficacious in the prevention of mixed 
episodes or in rapid cycling patients. The literature does not support the efficacy of 
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imipramine while, on the contrary, it gives some support for the efficacy of fluoxetine 
but only in BD-II patients. 
All except lithium and olanzapine were proven efficacious only in samples enriched 
for response or tolerability during the acute phase. Except from the negative data for 
lamotrigine there are no data concerning rapid cycling patients. Also, except from the 
data concerning olanzapine, there are no data concerning specifically the prevention 
of mixed episodes or the response of patients with an index mixed episode.  
 
3c.2. Comparison of treatments  
 
3c.2.1 Lithium vs. others 
 
There are a number of studies comparing lithium with carbamazepine (Placidi et al., 
1986; Watkins et al., 1987; Lusznat et al., 1988; Stoll et al., 1989; Small et al., 1991; 
Coxhead et al., 1992; Simhandl et al., 1993; Denicoff et al., 1997; Hartong et al., 
2003) including the MAP study (Greil et al., 1997; Greil and Kleindienst, 1999a, b; 
Kleindienst and Greil, 2000, 2002), and overall the data suggested that both agents are 
comparable in terms of efficacy. There are some data in favour of a superiority of 
lithium in the treatment of more ‘classic’ patients, but in the rest of patients the two 
agents seem to be comparable. Lithium was also comparable to valproate in terms of 
prevention of mood episodes  (Bowden et al., 2000; Calabrese et al., 2005a) and 
suicidality (Oquendo et al., 2011),  to olanzapine (Tohen et al., 2005) and also to 
aripiprazole (El-Mallakh et al., 2012)  
Furthermore, there was a difference in the clinical profiles of lithium and lamotrigine. 
As mentioned before, 3 placebo-controlled RCTs suggest that lamotrigine was more 
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efficacious in the prevention of depressive episodes and lithium in the prevention of 
manic, hypomanic, and mixed episodes (Bowden et al., 2003; Calabrese et al., 
2003b). 
When compared to antidepressants, the available data suggest that lithium is superior 
to imipramine for the prevention of depression in BD-I patients episodes (Prien et al., 
1973a; Prien et al., 1984) but inferior to fluoxetine in BD-II patients (Amsterdam and 
Shults, 2010).  
A maintenance study reported equal efficacy between venlafaxine and lithium in the 
prevention of depressive relapses although there was a tendency of better performance 
for venlafaxine (Amsterdam et al., 2015) 
 
3c.2.2 Antiepileptics vs. others 
 
The studies comparing valproate with lithium have already been discussed above 
(Bowden et al., 2000; Calabrese et al., 2005a; Oquendo et al., 2011). Two trials 
suggested valproate is comparable with olanzapine (Tohen et al., 2003a) and with a 
similar cost to healthcare system (Zhu et al., 2005). Carbamazepine has been studied 
only in comparison to lithium and these studies have been discussed previously in the 
paragraph concerning lithium (Placidi et al., 1986; Watkins et al., 1987; Lusznat et al., 
1988; Small et al., 1991; Coxhead et al., 1992; Simhandl et al., 1993; Denicoff et al., 
1997; Greil et al., 1997; Greil and Kleindienst, 1999a; Kleindienst and Greil, 2000, 
2002; Hartong et al., 2003). 
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3c.2.3 Olanzapine vs. others 
 
The comparison of olanzapine with lithium (Tohen et al., 2005) and valproate (Tohen 
et al., 2003a; Zhu et al., 2005) have been discussed above. 
One study which constituted the extension of an acute phase trial suggested that 
olanzapine is comparable with asenapine (McIntyre et al., 2010a) while another 
suggested that it is superior to paliperidone ER (Berwaerts et al., 2012a) and to long-
acting risperidone (Vieta et al., 2012). 
 
3c.2.4 Other comparisons 
 
The comparisons of aripiprazole (El-Mallakh et al., 2012), fluoxetine (Amsterdam 
and Shults, 2010) imipramine  (Prien et al., 1984) and lamotrigine (Bowden et al., 
2003; Calabrese et al., 2003b) with lithium, and of asenapine (McIntyre et al., 2010a), 
paliperidone and risperidone with olanzapine (Berwaerts et al., 2012a; Vieta et al., 
2012) have been discussed previously. 
One 25 week RCT comparing the OFC vs. lamotrigine in the prevention of bipolar 
depression reported that bipolar depressive patients who responded to OFC do better 
on long-term OFC in comparison to spontaneously improved patients on long-term 
lamotrigine  (Brown et al., 2009). The result is difficult to interpret as there was an 
enrichment of the OFC arm, but not the lamotrigine arm. Finally, one study compared 
the efficacy of venlafaxine in the prevention of bipolar vs. unipolar depression and 
reported no difference between groups (Amsterdam and Garcia-Espana, 2000). 
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3c.3. Combination and add-on treatment 
 
3c.3.1. Combination treatment 
 
There are three early studies which investigated the combination of lithium with 
another agent. The lithium plus imipramine combination was not more efficacious 
than lithium monotherapy (Kane et al., 1982; Prien et al., 1984) and lithium or 
carbamazepine monotherapy was not inferior to their combination which, however, 
was more efficacious in rapid cycling patients (Denicoff et al., 1997). Also the 
combination of lithium, carbamazepine, or valproate with perphenazine was not better 
than mood stabilizer monotherapy; on the contrary, combination treatment was 
associated with a shorter time to depressive relapse, more drop-outs, and increased 
rates of dysphoria and depressive symptoms (Zarate and Tohen, 2004). Similarly 
negative were the results for the lithium or valproate combination with olanzapine 
(Tohen et al., 2004) while, on the contrary, the combination with quetiapine had 
significant advantages irrespective of index episode, mood stabilizer and rapid cycling 
status (Vieta et al., 2008a; Suppes et al., 2009). Positive results were also reported for 
their combination with ziprasidone (Bowden et al., 2010). Results were negative for 
aripiprazole plus valproate (Woo et al., 2011) or lamotrigine (Carlson et al., 2012). 
The OFC was similar to lamotrigine in terms of incidence of relapse but overall 
bipolar depressive patients who responded to OFC do better on long-term OFC in 
comparison to spontaneously improved patients on long-term lamotrigine  (Brown et 
al., 2009). Lamotrigine plus divalproex was not superior to lamotrigine alone 
concerning the time to depressive episode (Bowden et al., 2012). 
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The open-label BALANCE study results neither reliably confirmed nor refuted a 
benefit of valproate-lithium combination therapy compared with lithium 
monotherapy, but clearly demonstrated that it is superior to valproate alone (Geddes 
et al., 2010). Another study reported that risperidone or olanzapine adjunctive therapy 
for 24 weeks is beneficial but continuation of risperidone beyond this period does not 
reduce the risk of relapse. Whether continuation of olanzapine beyond this period 
reduces relapse risk remains unclear but the potential benefit needs to be weighed 
against an increased risk of weight gain (Yatham et al., 2015). 
Overall, there is no compelling data that combination treatment in general does better 
than monotherapy. Patients stabilized on combination treatment might, however, do 
worse if shifted to monotherapy, and combination treatment with quetiapine or 
ziprasidone plus a mood stabilizer might work better than a mood stabilizer alone. 
 
3c.3.2. Add-on treatment 
 
A small study supported the adding of phenytoin to treatment as usual (Mishory et al., 
2003) as did another small one for gabapentin (but not on top of antipsychotics) 
(Vieta et al., 2006). The data are negative for the addition of oxcarbazepine (Vieta et 
al., 2008c) and equivocal for lamotrigine (van der Loos et al., 2011) to lithium. 
Negative data were also reported from a trial of adjunctive pramipexole to treatment 
as usual (TAU) in stabilized BD patients with the aim to improve neurocognition 
(Burdick et al., 2011), and from a trial of N-acetyl cysteine on TAU in patients after 
an index episode of bipolar depression (Berk et al., 2012).  It is interesting that 
adjunctive RLAI on TAU significantly prolongs the time to relapse in rapid cycling 
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patients (Macfadden et al., 2009). Adding aripiprazole to lithium or valproate also 
supplied positive results (Marcus et al., 2011). 
It is reported that patients who respond to treatment with lithium, valproate or 
carbamazepine plus antidepressants are more likely to maintain response with 
continuation of the combined treatment; however, those patients who manifest only a 
partial acute response are unlikely to further improve when the same treatment is 
continued (Altshuler et al., 2009). Also adjunctive asenapine to lithium or valproate 
was well tolerated for up to 52 weeks, but no efficacy data were reported from that 
trial (Szegedi et al., 2012).  
Two trials investigated the efficacy of adjunctive N-acetyl cysteine (NAC). The first 
one randomized 75 BD patients during the maintenance phase and reported that NAC 
treatment caused a significant improvement on the MADRS score in comparison to 
placebo (p=0.002). Improvements were lost after washout. There was no effect of 
NAC on time to a mood episode and no significant between-group differences in 
adverse events (Berk et al., 2008) The second randomized 14 patients (not all of them 
with high depression scores) and reported a superiority of the NAC group vs. placebo 
in terms of remission (p=0.031) (Magalhaes et al., 2011b). One maintenance study 
supported the usefulness of ramelteon in the prevention of relapse in BD patients 
(Norris et al., 2013) Negative results have been reported for the usefulness of 
memantine in patients on valproate treatment (Lee et al., 2014b). 
There are some studies suggesting that there is a role for various nutritional 
supplements such as n-3 fatty acids, chromium, choline, magnesium and tryptophan 
alone or in combination with pharmacotherapies for the treatment of BD but the data 
are of low quality (Sylvia et al., 2013) 
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3c.4. Post-hoc, reviews and meta-analytic studies 
 
3c.4.1 Post-hoc analyses 
 
A number of post-hoc analyses exist and attempt to answer questions that the original 
papers did not address. Post-hoc analysis can be informative but can also be a major 
source of publication bias (Vieta, 2007). A subanalysis of the MAP study reported 
that lithium was superior in ‘classical’ BD-I patients and comparable with 
carbamazepine in the rest. An additional sub-analyses including mixed states as an 
additional non-classical feature confirmed the results (Greil et al., 1998). 
Concerning the usefulness of antidepressants, one post-hoc analysis suggested that the 
discontinuation rate for any reason was lower among patients in the divalproex group 
taking a selective serotonin re-uptake inhibitor (SSRI) than among patients in the 
placebo group taking an SSRI (Gyulai et al., 2003b) while the application of four 
different remission criteria suggested that the application of different definitions of 
remission does not make any significant difference concerning the results (Pae et al., 
2012). The addition of an atypical antipsychotic-antimanic agent in some BD patients 
might help to reduce suicidal ideation (Houston et al., 2006). Olanzapine might be 
more beneficial if started at an earlier stage of the disease (Ketter et al., 2006), and it 
is also efficacious in patients with an index mixed episode (Tohen et al., 2009).  
Concerning lithium, it has been reported that only at plasma levels between 0.6-1.2 
mEq/lt it is efficacious in the prevention of both manic and depressive episodes 
(Nolen and Weisler, 2013). Another post-hoc analysis did not confirm its efficacy in 
the prevention of depressive episodes while it confirmed the efficacy of lamotrigine in 
the prevention of both manic and depressive episodes irrespective of index episode 
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(Calabrese et al., 2003a; Goodwin et al., 2004). These results still held true when 
early relapses that occurred in the first 90 or 180 days were excluded from the 
analysis (Calabrese et al., 2006). The lack of efficacy of lithium in a subgroup of 
patients might be due to lithium induced thyroid function abnormalities in a 
subpopulation of patients (Frye et al., 2009). Overall, lamotrigine performed better in 
comparison with lithium in terms of remission and the persistence of subsyndromal 
symptoms (Frye et al., 2006). Some positive results for NAC were also suggested by 
two post-hoc analysis (Magalhaes et al., 2011a, 2013) 
 
3c.4.2 Review and meta-analyses 
 
One review confirmed the efficacy of lithium but reported that there is no definitive 
evidence as to whether or not lithium has an anti-suicidal effect (Burgess et al., 2001). 
A more recent meta-analysis confirmed the antisuicidal effect of lithium vs. placebo 
but not its superiority over other agents except carbamazepine (Cipriani et al., 2013). 
Two other studies support the usefulness of RLAI (Bobo and Shelton, 2010) and of 
ziprasidone for the maintenance treatment of BD-I disorder in adults as an adjunct to 
lithium or valproate (Citrome, 2010). Another review identified four issues that limit 
the interpretation of trials (insufficient duration, enriched sample, possible conflation 
with iatrogenic adverse effects by abrupt medication discontinuation with beneficial 
effects on treatment, and a low overall completion rate) (Tsai et al., 2011).  
Concerning meta-analysis, the first one for carbamazepine failed to prove the 
prophylactic efficacy (Dardennes et al., 1995). A second one concluded that the data 
for oxcarbazepine are of very low quality not allowing firm conclusions (Vasudev et 
al., 2008). A fair number of meta-analyses focused on lithium. One confirmed its 
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efficacy but failed to find sufficient evidence to prove that a lithium-withdrawal 
relapse phenomenon exists, that is patients relapse soon after stopping lithium and the 
symptomatology turns refractory to treatment (Davis et al., 1999). Another one 
supported an anti-suicidal efficacy of lithium (Tondo et al., 2001). Three others 
confirmed the prophylactic anti-manic efficacy of lithium but were equivocal for the 
prophylactic efficacy against depressive episodes (Burgess et al., 2001; Geddes et al., 
2004; Severus et al., 2014). 
Furthermore, a number of meta-analytic studies confirmed the prophylactic antimanic 
efficacy of specific agents and the anti-depressant of others. It is important to mention 
that among other more or less expected results, the antidepressant efficacy of 
valproate and imipramine was supported (Beynon et al., 2009) as well as of lithium 
(Popovic et al., 2010), while the prophylactic antidepressant efficacy of olanzapine 
was questioned (Cipriani et al., 2010). Antipsychotics might be superior to lithium 
and anticonvulsants but with more adverse effects (Vazquez et al., 2015b; Vazquez et 
al., 2015a). 
The issue of combination treatment has been the focus of two meta analyses. They 
both reported negative conclusions for the addition of antidepressants (Ghaemi et al., 
2008; Beynon et al., 2009). A third analysis suggested that no monotherapy was 
associated with a significantly reduced risk for both manic/mixed and depressive 
relapse, and only quetiapine plus lithium or divalproex was associated with a 
significantly reduced risk for relapse towards both the manic/mixed and depressive 
pole (Vieta et al., 2011). This specific meta-analysis also pointed out that the majority 
of studies included samples enriched for response to a specific agent during the acute 
phase.  
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Finally, pharmaco-epidemiological data suggest that valproate and lithium might have  
a protective effect against any psychiatric hospitalization for patients with BD in a 
real world setting while lamotrigine and carbamazepine might exert protective effects 
solely against depressive and manic episodes, respectively (Joas et al., 2015).  
 
3.d. Treatment of mixed episodes 
 
Mixed episodes are no longer accepted as a diagnostic entity by DSM-5; instead 
‘mixed features’ is included as a specifier and this creates a degree of confusion for 
future treatment recommendations since the two concepts differ significantly 
(Fountoulakis, 2015d). So far, mixed episodes have been combined with pure manic 
episodes in RCTs and results have been reported together. Only few papers – usually 
post-hoc analyses- report the results concerning mixed episodes separately. 
Unfortunately all data on mixed episodes stem from trials of acute mania and only one 
trial reports on the efficacy of lurasidone in bipolar depressive patients with mixed 
features. That trial supported the efficacy of lurasidone in these patients for the 
improvement of both depressive and manic symptoms (McIntyre et al., 2015; Suppes 
et al., 2015). Another important limitation is that the results reported usually concern 
only the manic but not the depressive component of the mixed episode (Fountoulakis 
et al., 2012b).  The ranking of the data for the treatment of mixed episodes is shown in 
table 6. 
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3.d.1 Treatment of acute mixed episodes 
 
Aripiprazole and carbamazepine were found efficacious in the treatment of both the 
manic and the depressive component of acute mixed episodes (Keck et al., 2003b; 
Weisler et al., 2004; Weisler et al., 2005; Sachs et al., 2006; Weisler et al., 2006; 
Suppes et al., 2008b). Ziprasidone was also found to be efficacious against both 
components, but the definition of mixed states was different from the DSM.  
Olanzapine and valproate were reported to be efficacious against mania but the data 
are inconclusive concerning the depressive component (Tohen et al., 1999; Tohen et 
al., 2000; Baker et al., 2003; Baldessarini et al., 2003b; Shi et al., 2004a; Bowden et 
al., 2006; Ghaemi et al., 2007; McIntyre et al., 2009b). The post-hoc analysis of the 
two bipolar depressive trials suggested that olanzapine was efficacious in those 
patients with mixed features suggesting an effect also on the depressive component 
(Tohen et al., 2014). Furthermore, risperidone but not asenapine is reported to be 
efficacious against the manic component but no data exist concerning their efficacy 
on the depressive component (Khanna et al., 2005; McIntyre et al., 2009b). A post 
hoc analysis suggested that asenapine but not olanzapine improved the quality of life 
in mixed patients (Michalak et al., 2014) and another two suggested that asenapine 
improved both the manic and depressive component in comparison to placebo and 
was also found superior to olanzapine concerning the manic but not the depressive 
component (McIntyre et al., 2013; Berk et al., 2015). However a more recent trial was 
negative (Landbloom et al., 2016). Paliperidone was efficacious only against the 
manic component (Vieta et al., 2010c; Berwaerts et al., 2012b). One study for 
quetiapine was a failed one (Cutler et al., 2011). 
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The combination of olanzapine olanzapine plus lithium or valproate have positive 
data concerning both components (Tohen et al., 2002b; Baker et al., 2004; Houston et 
al., 2006; Houston et al., 2009; Houston et al., 2011). In mixed depression the OFC 
was comparable to olanzapine and both were superior to placebo but due to the small 
number of subjects the report does not permit to derive conclusions (Tohen et al., 
2003c; Benazzi et al., 2009). The data concerning the combination of haloperidol or 
risperidone plus lithium or valproate were negative (Sachs et al., 2002). Overall it 
seems that second generation antipsychotics (SGAs) are effective in treating acute 
mixed episodes of BD, with predominant manic symptoms. Their efficacy in treating 
depressed mixed episodes remains unclear (Muralidharan et al., 2013).  
The only trial in patients in bipolar depressive episode with mixed features supported 
the efficacy of lurasidone in these patients for the improvement of both depressive 
and manic symptoms (McIntyre et al., 2015; Suppes et al., 2015). 
 
3.d.2 Maintenance treatment of mixed bipolar episodes 
 
The data so far suggest that olanzapine prolongs time to relapse into any episode in 
patients with an index mixed episode (Tohen et al., 2006; Tohen et al., 2009) while on 
the contrary, lithium and valproate had negative results in patients with a dysphoric 
manic index episode (Bowden et al., 2005a). Additionally, the data are in support of 
the combination of quetiapine plus lithium or valproate (Vieta et al., 2008a; Suppes et 
al., 2009) but are negative concerning aripiprazole in patients with an index mixed 
episode (Yatham et al., 2013a). 
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3.e. Treatment of rapid cycling patients 
 
The treatment of rapid cycling patients constitutes a challenge. Often their course 
frustrates the therapist and the evaluation of treatment is difficult because of the rapid 
switching from one pole to another (Fountoulakis et al., 2013). The ranking of the 
treatment of rapid cycling patients is shown in table 7  
 
3.e.1. Treatment of acute episodes in rapid cycling patients 
 
Olanzapine is effective in reducing symptoms of mania and was well tolerated in 
rapid cycling BD-I patients as shown by a secondary analysis (Sanger et al., 2003). 
The pooling of data from two RCTs reported that improvement of mania with 
olanzapine was similar in rapid cyclers and non-rapid cyclers. However, rapid cyclers 
showed an earlier response (Vieta et al., 2004). One trial was also positive concerning 
aripiprazole in acutely manic rapid cycling patients (Sachs et al., 2006). 
Although one study on acute mania in rapid cycling patients was a failed one (Cutler 
et al., 2011), one a priori planned sub-analysis of data from rapid cycling patients 
with acute BD-I or BD-II depression suggested that quetiapine monotherapy (300-600 
mg/day) was effective and well tolerated (Vieta et al., 2007). The post-hoc analysis of 
the rapid cycling subsample of bipolar depressives from the BOLDER study 
confirmed this (Cookson et al., 2007) and finally the sub-analysis of the data from a 
small number of depressed rapid cycling BD patients again suggested that 300mg of 
quetiapine monotherapy was superior to placebo (Suppes et al., 2010).  
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It seems that lithium has a week but positive effect (Young et al., 2010) and also there 
are some positive but equivocal data for valproate (Muzina et al., 2010). On the other 
hand, the data are clearly negative for paroxetine (McElroy et al., 2010c). 
The combination of lithium and divalproex was not effective and the further addition 
of lamotrigine did not seem to add anything in terms of efficacy (Kemp et al., 2012b) 
 
3.e.2. Relapse prevention in rapid cycling patients 
 
For the prevention phase, the data so far suggest that divalproex is not more effective 
than lithium (Calabrese et al., 2005a) and also that the combination of lithium plus 
divalproex is not better than lithium alone (Kemp et al., 2009). One small study 
reported that the combination of lithium plus carbamazepine did better than either 
agent alone (Denicoff et al., 1997). It is interesting that the data are negative for 
lamotrigine although in some secondary outcomes there was a beneficial signal 
especially in BD-II patients (Calabrese et al., 2000). Overall, the widely believed 
concept among clinicians that divalproex is more effective than lithium in the long-
term management of rapid-cycling bipolar disorder was not supported by a trial on 
139 patients (Findling et al., 2005). 
One post-hoc analysis suggested that aripiprazole was efficacious (Muzina et al., 
2008). There are no data on other antipsychotics in monotherapy concerning the 
maintenance phase. A post hoc analysis reported that rapid cycling patients did less 
well during the extended observation period than non-rapid cycling patients, 
regardless of treatment and that overall olanzapine and divalproex appeared 
comparable (Suppes et al., 2005). 
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Another study confirmed the efficacy and safety of quetiapine add-on to lithium or 
divalproex in the prevention of mood episodes in rapid cycling BD-I patients with 
most recent episode manic/mixed or depressive (Vieta et al., 2008a). There was a 
North American study with a similar design as the previous one reporting similar 
results (Suppes et al., 2009). A large controlled trial which evaluated adjunctive 
maintenance treatment with RLAI on TAU in 240 BD-I patients with at least four 
mood episodes in the 12 months prior to study entry yielded positive results 
(Macfadden et al., 2009). 
The results of the STEP-BD support a role of antidepressants in the development of 
rapid cycling in a subpopulation of BD patients (Schneck et al., 2008; Ghaemi et al., 
2010). A similar conclusion came from earlier randomized controlled study of rapid 
cycling patients using a double-blind on-off-on-off design with the use of tricyclic 
antidepressants (Wehr et al., 1988)  
Finally, the data are negative concerning the administration of 6 g/day of ethyl-
eicosapentanoate (EPA) as augmentation of treatment with mood stabilizers in rapid 
cycling patients with bipolar depression (Keck et al., 2006b).  
One meta analysis suggested that lithium is at least partially efficacious in rapid 
cycling patients (Kupka et al., 2003), another one suggested there is no clear 
advantage of any treatment option vs. the others (Tondo et al., 2003), while a third 
one proposed that some atypical antipsychotics (especially quetiapine and olanzapine) 
may be considered as the first-line treatment options (Cruz et al., 2010). The meta-
analysis of 20 studies published from 1974-2002 comparing subjects with rapid and 
non-rapid cycling BD reported that in contrast to common beliefs, lithium prophylaxis 
has at least partial efficacy in a considerable number of rapid cyclers, especially when 
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antidepressants are avoided. Hypothyroidism may be associated with mood 
destabilization in vulnerable patients (Kupka et al., 2003).  
 
3.f. Treatment of special conditions 
 
3.f.1. Treatment of comorbid conditions 
 
Comorbidities are common in bipolar patients and often need more elaborated 
therapeutic interventions (Fountoulakis, 2015e, f, g).  
 
3.f.1.1 Treatment of comorbid substance abuse disorder (SUD) 
 
There are two placebo controlled trials suggesting that the combination of valproate 
and lithium in BD patients with co-occurring alcohol dependence improves both 
mood and alcohol use symptoms (Salloum et al., 2005; Salloum et al., 2007) and that 
lithium treatment in BD adolescents improves mood and substance use symptoms. 
(Cerullo and Strakowski, 2007). Lithium can be used for the treatment of concomitant 
substance and polysubstance abuse (Geller et al., 1992; Geller et al., 1998), and 
quetiapine and risperidone can reduce drug craving (Nejtek et al., 2008). On the 
contrary, the data concerning quetiapine for alcohol abuse are negative (Brown et al., 
2008; Sherwood Brown et al., 2014). For bipolar patients with alcohol dependence, 
the opiate receptor antagonist naltrexone could be useful (Sherwood Brown et al., 
2009), and a preliminary report is positive for acamprosate (Tolliver et al., 2012) but 
negative concerning the treatment of any substance use with N-acetylcysteine 
(Bernardo et al., 2009). One trial on the usefulness of citicoline in the treatment of 
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cocaine use was inconclusive (Brown et al., 2015) as was one study with the use of 
topiramate in alcohol dependence (Sylvia et al., 2016). 
There are open-label medication trials which provide limited support to quetiapine, 
aripiprazole, bupropion and lamotrigine for the treatment of BD patients with cocaine 
dependence. Also, aripiprazole might be helpful in patients with alcohol use disorders 
(Cerullo and Strakowski, 2007; Sepede et al., 2014).  
Overall, while some data are available for alcohol, cannabis, and cocaine use 
comorbid with BD the evidence is sparse concerning heroin, amphetamine, 
methamphetamine, and polysubstance SUD comorbid with BD  (Beaulieu et al., 
2012).  
 
3.f.1.2 Treatment of comorbid anxiety and disorders 
 
A post hoc analysis of anxiety symptoms with data from 2 RCTs of 8-week duration 
of quetiapine (300 or 600 mg/day) (Calabrese et al., 2005b; Thase et al., 2006) 
reported that at endpoint there was no difference between treatment groups and 
placebo concerning the total HAM-A score, but there was a difference both for the 
psychic and the somatic anxiety subscale scores in comparison to placebo (p<0.001) 
(Lydiard et al., 2009). Also, quetiapine XR (50-300 mg/day) was superior both to 
divalproex ER (500-3000 mg/day) and placebo in the improvement of anxiety in BD 
patients with comorbid panic attacks or generalized anxiety disorder (GAD) (Sheehan 
et al., 2013).  In another study, again quetiapine (300 or 600 mg/day) and paroxetine 
(20 mg/day) produced a significant improvement in anxiety in terms of change of 
HAM-A scale score from baseline in acutely depressed BD patients (McElroy et al., 
2010c). Of note, quetiapine (300-600 mg/day) also significantly improved the HAM-
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D score from baseline while this was not the case with paroxetine (600-1800 mg/day; 
p=0.279) (Young et al., 2010). However, another study was negative for quetiapine 
concerning its effect on depression in BD patients with GAD (Gao et al., 2014).   
Lurasidone (20-60 mg/day; N=166 or 80-120 mg/day) also significantly improved 
anxiety symptoms in comparison to placebo (Loebel et al., 2014a).  
On the contrary, risperidone monotherapy was not an effective anxiolytic for BD 
patients with comorbid panic disorder or GAD in doses of 0.5-4 mg/day over 8 weeks 
of treatment (Sheehan et al., 2009), and similar results were obtained with ziprasidone 
(Suppes et al., 2014). 
The data concerning divalproex (rapidly titrated up to 2500 mg/day, as tolerated, to a 
target serum level of 50–100 mg/dl) are equivocal because the only positive study was 
based on a very small study sample (25 outpatients with BD-I depression) (Davis et 
al., 2005). 
It is reasonable to suggest that also benzodiazepines can be used as adjunctive 
medication for sedation or for the treatment of anxiety although abuse, tolerance and 
dependence constitute important problems. Although approved for the treatment of 
GAD, pregabalin has no data in BD. However, again it is reasonable to suggest it 
might be a useful agent for the treatment of anxiety disorders that commonly 
accompany BD and could substitute for benzodiazepines. A significant advantage is 
that it is not metabolized by the liver.  
There is one study suggesting that adjunctive topiramate could be beneficial in the 
treatment of BD with comorbid Obsessive Compulsive disorder (OCD) but the overall 
design and reporting of results does not permit reliable conclusions (Sahraian et al., 
2014). 
The ranking of the treatment of comorbid anxiety is shown in table 3. 
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3.f.1.3. Weight gain  
 
Topiramate is not effective in the treatment of BD per se, however it is unique 
because of its ability to cause weight loss at dosages of 50-200 mg/day. A review 
reported that more than 70% of patients taking topiramate for a mean duration of 5 
months lost a mean of 5-6 kilograms (Arnone, 2005). However topiramate might 
cause de novo depression and suicidality in some patients, although no completed 
suicides related to topiramate have been reported (Fountoulakis et al., 2012c). 
 
3.f.2. Treatment of Agitation   
 
Probably most clinicians would choose antipsychotics in severely agitated bipolar 
patients, and this option is supported by a double blind clinical trial which reported 
that intramuscular haloperidol (5-10 mg) was equal in efficacy but faster acting in 
comparison to intramuscular clonazepam (1-2 mg) in agitated mania at 0, 30 and 60 
minutes (Chouinard et al., 1993). Similarly, intramuscular olanzapine (10 mg, first 
two injections; 5 mg, third injection) was reported to be superior to lorazepam (2 mg, 
first two injections; 1 mg, third injection), for the control of agitation in manic 
patients. Already 2 hours after the first injection, patients treated with olanzapine 
showed a significantly greater reduction in scores on all agitation scales compared 
with patients treated with either placebo or lorazepam (Meehan et al., 2001). 
Valproate oral loading of 20 mg/kg/day was reported to be comparable to haloperidol 
0.2 mg/kg/day for the treatment of exited manic patients in a single blind study and 
the effect was evident within 3 days from starting (McElroy et al., 1996). Overall, 
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valproate loading up to 30 mg/kg/day was reported to be safe and well tolerated 
(Hirschfeld et al., 1999). 
Inhaled loxapine exerted an anti-agitation effect at 10 min at both the 5 mg and 10 mg 
doses and was superior to placebo at all-time points measured. For safety reasons it 
has been recommended that inhaled loxapine should be restricted to a single dose in 
24 h and needs to be subject to a Risk Evaluation and Mitigation Strategy program 
(Citrome, 2012; Kwentus et al., 2012). In Europe, two doses are allowed (the second 
must be given 2 hours after the initial inhalation) (Popovic et al., 2015). 
The issue of agitation with aripiprazole is controversial. As an adverse event it is not 
reported in the dataset and on the contrary, aripiprazole is a recommended evidence 
based treatment against agitation associated with schizophrenia or bipolar mania 
(Sanford and Scott, 2008; Gonzalez et al., 2013; Citrome et al., 2016). However it has 
been reported under naturalistic conditions (Di Lorenzo et al., 2007) and especially in 
vulnerable populations such as elderly patients (Coley et al., 2009). Agitation has also 
been described when initiating aripiprazole in patients after prolonged treatment with 
potent D2 blocking agents that may result in an upregulation of postsynaptic 
dopamine receptors (Lea et al., 2007). However, a major obstacle for a fair estimate of 
the rate of agitation with aripiprazole is that akathisia can easily be mistaken as 
agitation (Thomas et al., 2015), especially by less experienced raters. 
 
3.f.3. Treatment of neurocognitive deficits 
 
The presence of a significant neurocognitive deficit in BD patients has been solidly 
shown and it concerns all phases of the disorder, including periods of euthymia 
(Tsitsipa and Fountoulakis, 2015). Galantamine may have specific benefits for 
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episodic memory, but not processing speed, in patients with cognitive impairment as 
part of BD (Ghaemi et al., 2009). One study reported that pramipexole may improve 
neurocognition in euthymic patients only (Burdick et al., 2012) while the data are 
negative for N-acetyl cysteine (NAC) (Dean et al., 2012).  
Adjunctive intranasal insulin (40 IU q.i.d.; N=34) had a beneficial effect on executive 
function but not on the other neurocognitive measures in euthymic patients (McIntyre 
et al., 2012a). Also adjunctive mifepristone, which is a synthetic steroid, at 600 
mg/day improved spatial working memory in BD depressed patients, and this was 
evident also 7 weeks after the cessation of treatment (Watson et al., 2012) 
ECT was reported to produce an improvement in neurocognitive function similar to 
that of algorithm-based pharmacological treatment (Kessler et al., 2014). 
 
3.f.4. Suicide 
 
There is much discussion concerning the potential anti-suicidal efficacy of specific 
drugs and especially of lithium. However almost all the data come from studies of 
naturalistic and epidemiological nature and no controlled studies exist.  
There is only one post-hoc analysis which investigated suicidality in BD-I patients 
during treatment with olanzapine in combination with lithium or divalproex. In mixed 
patients with residual suicidality, suicidal thoughts were associated with somatic 
discomfort, agitated depression, and psychosis. It seems that combination therapy 
with olanzapine plus lithium (N=36) vs. lithium alone (N=22) significanlty reduced 
the score in the suicidal item of the HAM-D by 58% vs. 29% (p<0.05) within 1 week, 
and all associated symptoms within 2 weeks by averages of 31% vs. 12% (p<0.05) 
(Houston et al., 2006). The analysis of pharmaco-epidemiological data suggest that 
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treatment with lithium but not with valproate is associated with lower suicidality 
(Goodwin et al., 2003; Song et al., 2015). 
 
3.g. Non-biological treatment options 
 
There are some but overall limited data concerning the usefulness of specific 
adjunctive psychotherapies (Reinares et al., 2014; Miziou et al., 2015). Research so 
far has focused on acute depression and the maintenance phase but not on acute 
mania. These studies suffer from the same limitations and methodological problems 
as all psychotherapy trials do. There is no universally accepted standardized method 
to conduct this kind of studies and blinding and the nature of the control intervention 
are unresolved limitations. The grading of these treatment options is shown in table 8. 
 
3.g.1. Cognitive-behavioral therapy (CBT) 
 
The overall data for the long-term efficacy of CBT either as monotherapy or as add on 
to psychoeducation, and in comparison to TAU are negative concerning relapse 
prevention. However, there are some positive results for the acute depressive phase in 
BD (Ball et al., 2006; Scott et al., 2006; Zaretsky et al., 2008; Costa et al., 2011; 
Gomes et al., 2011; Meyer and Hautzinger, 2012; Gonzalez Isasi et al., 2014). A post 
hoc analysis suggested that CBT could be more effective than TAU in patients with 
less than 12 previous episodes, but less effective in those with more episodes (Scott et 
al., 2006). In BD patiens with insomnia, CBT for insomnia was superior to 
psychoeducation concerning manic relapses (Harvey et al., 2015). 
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3.g.2. Psychoeducation 
 
The data on adjunctive psychoeducation suggest that -in comparison to TAU or to 
non-specific intervention- it prevents relapse to both poles if administered to patients 
in clinical remission (Perry et al., 1999; Colom et al., 2003; Colom et al., 2009; 
Lobban et al., 2010; de Barros et al., 2013) but it has no effect on biological rhythms 
(Cardoso Tde et al., 2015). Again a post-hoc analysis suggested that patients with 
more than 7 episodes did not show significant improvement with group 
psychoeducation for time to recurrence, and those with more than 14 episodes did not 
benefit from the treatment in terms of time spent ill (Colom et al., 2010). A systematic 
review confirmed the above (Bond and Anderson, 2015). 
 
3.g.3 Interpersonal and social rhythm therapy (IPSRT) 
 
Overall there are no convincing data on the usefulness of IPSRT during the 
maintenance phase of BD, however there are some data suggesting that if applied 
early and particularly already during the acute phase, it might prolong the time to 
relapse (Frank et al., 2005; Frank et al., 2008; Swartz et al., 2012; Inder et al., 2015). 
 
3.g.4. Family Focus Treatment (FFT) 
 
Overall the literature supports the idea that interventions which focus on families and 
caregivers exert a beneficial impact especially on family members, but the effect on 
the patients themselves is controversial and uncontrolled. Probably it improves issues 
like treatment adherence and family dynamics (Miklowitz et al., 2000; Miklowitz et 
 by guest on N
ovem
ber 17, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pt
ed
 M
an
us
cr
ipt
79 
 
al., 2003; Rea et al., 2003; Reinares et al., 2004; Reinares et al., 2008; D'Souza et al., 
2010) 
 
3.g.5. Intensive psychosocial intervention 
 
‘Intensive’ psychotherapy is another option but it is of unknown efficacy with limited 
research support (Miklowitz et al., 2007b; Miklowitz et al., 2007a). The term refers to 
up to 30 sessions of CBT, IPSRT, or FFT within 9 months. 
 
3.g.6. Cognitive remediation and functional remediation.  
 
The data are positive in improving functioning, which is the critical endpoint, but 
mostly negative concerning cognitive outcomes when using cognitive remediation 
techniques as add on to TAU in BD patients (Martinez-Aran et al., 2011; Lahera et 
al., 2013; Torrent et al., 2013) although a more recent post hoc analysis was 
promising (Sole et al., 2014). 
 
3.g.7. Mindfulness-based interventions (MBCT).  
 
Overall the data do not support a beneficial effect of MBCT on the core symptoms of 
BD but also suggest that MBCT could be useful in the reduction of anxiety in BD 
patients. So far there are no data supporting its efficacy in the prevention of 
recurrences. (Williams et al., 2008; Ives-Deliperi et al., 2013; Perich et al., 2013a; 
Perich et al., 2013b). 
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3.g.8 Internet-based interventions 
 
There is only one randomized trial which compared a completely Internet-based 
preventive program for bipolar disorder, adjunctive to usual pharmacological 
management vs. a control intervention. The results suggested no differences between 
treatment groups (Barnes et al., 2015). The design of the study precludes deriving 
general conclusions for the efficacy of web-based approaches. Another study which 
combined psychoeducation with mobile phone technology did not show any benefit 
vs. paper and pencil method, however this could mean that a mobile phone approach 
could be an important alternative without compromising the outcome (Depp et al., 
2015). 
 
4. Safety issues with pharmacotherapy of BD 
 
A comprehensive grading of all agents in terms of their safety and tolerability profile 
is shown in table 9. 
 
4.a. Lithium 
 
Lithium has a narrow therapeutic window concerning its dosage and plasma levels 
(recommended plasma level 0.6-1.2 mmol/L), and laboratory testing and thorough 
investigation before starting lithium treatment (ECG; kidney function etc.) is 
necessary. Unfortunately this often delays the initiation of treatment. Adverse events 
are more frequent with higher doses, while ‘rebound mania’ has been described upon 
withdrawal. The most frequent adverse events include neurological, endocrinological 
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(more often from the thyroid), cardiovascular, renal, gastrointestinal, hematological 
and dermatological manifestations, and lithium intoxication is not rare. In clinical 
practice patients often complain of sedation, tremor and sometimes a decline in 
creative thinking (Shaw et al., 1986; Engelsmann et al., 1988; Stoll et al., 1996). A 
general negative impact of lithium on neurocognitive function has been reported 
(Karniol et al., 1978; Kropf and Muller-Oerlinghausen, 1979; Reus et al., 1979; 
Squire et al., 1980; Connelly et al., 1982; Lund et al., 1982; Shaw et al., 1987; 
Engelsmann et al., 1988; Maarbjerg et al., 1988; Kocsis et al., 1993; Kessing, 1998; 
Honig et al., 1999; Bora et al., 2007; Senturk et al., 2007; Goldberg, 2008). It seems 
that there is a complex relationship between lithium treatment, female gender, 
hypothyroidism and rapid cycling (Cowdry et al., 1983; Bauer and Whybrow, 1990; 
Bauer et al., 1990; Gyulai et al., 2003a; Fountoulakis et al., 2008b). While most 
authors argue that lithium is neuroprotective, a neurotoxic effect is also possible in the 
long term, even at therapeutic levels, especially in combination with antipsychotics 
(Fountoulakis et al., 2008b).  Comprehensive guidelines concerning lithium treatment 
and optimal therapeutic serum levels are available and should be applied (Malhi et al., 
2011), and a recent review provides up-to-date information on its safety (Murru et al., 
2015). 
 
4.b Antiepileptics 
 
The recommended therapeutic valproate serum concentration is 50-150 mg/mL. It is 
not recommended to be used in women of childbearing age, due to the high frequency 
of unplanned pregnancies in bipolar females, and the relatively high teratogenicity of 
valproate. Other potential acute side effects are weight gain and hair loss. Its use has 
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been associated with polycystic ovary syndrome (PCOS). It is to be noted however, 
that similar to epilepsy, there is an association between PCOS and major psychiatric 
disorders, including BD. An increased risk can also be demonstrated in their siblings 
suggestive of shared familial factors between PCOS and psychiatric disorders (Cesta 
et al., 2016). 
The typical dosage of carbamazepine in the treatment of acute mania is 600-1800 
mg/day (serum concentration 4-12 mg/mL). After several weeks under 
carbamazepine, an induction of hepatic enzymes (CYP 3A4) occurs, the drug levels 
drop and may require additional upward dose titration (Bertilsson and Tomson, 1986). 
The dosage-related adverse effects include double or blurred vision, dizziness, 
sedation, ataxia, vertigo, gastrointestinal disturbances, cognitive impairment, 
hematological effects and Stevens-Johnson syndrome including its related 
dermatologic effects (Tohen et al., 1991; Tohen et al., 1995; Blackburn et al., 1998). 
The most significant drawback of lamotrigine treatment is the need to initiate it at 25 
mg/day for two weeks, then 50 mg/day for another two weeks and then by increments 
of 25-50 mg/day thereafter to avoid a moderately high incidence of rash (Seo et al., 
2010) 
Carbamazepine decreases lamotrigine concentrations by approximately 50%, and in 
combination therapy, lamotrigine can be started with higher dosages and faster 
titration. Vice versa, when combined with valproate a slower titration scheme is 
needed for lamotrigine., Carbamazepine induces the metabolism of other agents as 
well, e.g., risperidone (Ono et al., 2002). 
It is also important to note the adverse effects of topiramate because although it is not 
used in the treatment of BD per se, it is often administered in BD patients in order to 
lose weight or to treat a comorbid substance abuse disorder. It is reported that 
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topiramate impairs attention, verbal memory, psychomotor speed, and word-finding 
even at very low dosages (25-50 mg/day). This impairment is reversible after 
discontinuation of the drug (Salinsky et al., 2005; Goldberg, 2008). 
An important recent development was the safety warning by the FDA after a meta 
analysis which suggested that antiepileptics might double the suicidal risk (FDA, 
2008). The field remains uncertain, with some reports and authors supporting the 
FDA warning (Nilsson et al., 2002; Mula and Sander, 2007; Gibbons et al., 2009; 
Andersohn et al., 2010; Arana et al., 2010; Olesen et al., 2010; Patorno et al., 2010; 
VanCott et al., 2010; Ziemba et al., 2010; Wen et al., 2011; Fountoulakis et al., 
2012c; Pugh et al., 2012; Siamouli et al., 2014).  It is important to note that suicidality 
data came from the registration of adverse events rather than from systematically 
collected data (Hesdorffer and Kanner, 2009). However, it seems clear that 
topiramate, lamotrigine and levetiracetam are related to increased suicidality in non-
psychiatric patients and this should be the focus of further research. 
 
4.c. Antipsychotics 
 
The adverse effects of FGAs include EPS, tardive dyskinesia and hyperprolactinaemia 
and the life-threatening but rather rare neuroleptic malignant syndrome, while the 
most frequent side effects of chlorpromazine are EPS, tardive dyskinesia, postural 
hypotension and hepatotoxicity.  
On the other hand, the most significant problem with some of the second generation 
antipsychotics (SGAs) is weight gain, hyperlipidaemia and diabetes mellitus. The 
treatment of these somatic conditions is difficult and the methods proposed have 
produced rather unsatisfactory results so far. Hyperprolactinaemia and EPS are the 
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most frequent adverse effects with amisulpride. Akathisia and EPS are the adverse 
effects most often reported with aripiprazole.  
Concerning olanzapine, the most frequent adverse effects include dry mouth, weight 
gain, increased appetite, diabetes mellitus and metabolic syndrome and somnolence. 
The main adverse effects of quetiapine are persistent sedation and weight gain, 
however, to a lower extent than olanzapine. Maybe the XR formulation of quetiapine 
induces less sedation in comparison to the IR formulation (Riesenberg et al., 2012). 
The main side effects of risperidone are dose-related EPS, weight gain, sedation and 
hyperprolactinemia. Somnolence, akathisia and EPS, as well as a significant QTc 
prolongation are the main adverse effects of ziprasidone treatment, however 
ziprasidone is not associated with the metabolic syndrome (Kemp et al., 2012a) 
Reports on antipsychotics concerning adverse effects on neurocognition are rare and 
conflicting (Holmes et al., 2008; Goldberg and Chengappa, 2009; Pan et al., 2011). 
There are data suggesting that an executive function deficit is correlated with years of 
exposure to antipsychotic drugs (Zubieta et al., 2001). This latter finding could reflect 
either the toxic effect of chronic psychosis, the toxic effect of long term medication or 
both. Current antipsychotic treatment in BD patients is reported to relate to worse 
performance in sustained attention and visuomotor speed, across all executive 
function tests as well as in semantic fluency, verbal learning and recognition memory, 
even when studies were controlled for differences in clinical features (King, 1994; 
Altshuler et al., 2004; Frangou et al., 2005; Jamrozinski et al., 2009).   
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4.d. Antidepressants 
 
There is a number of different adverse effects caused by antidepressants. Most of 
them are not severe, may cause significant burden to the patients but usually improve 
with time (NHS, 2014). 
The adverse effects of SSRIs and serotonin and norepinephrine re-uptake inhibitors 
(SNRIs) include agitation, shakiness, anxiety or feeling of being sick, indigestion, 
stomach aches, diarrhoea or constipation, loss of appetite, dizziness, insomnia and 
other sleep disorders, or, on the contrary, hypersomnia and sedation, headache, loss of 
libido, weight gain, excessive sweating, hyponatriaemia (especially in the elderly) and 
sexual dysfunction. The adverse effects of tricyclic antidepressants (TCAs) include: 
dry mouth, blurred vision, constipation, dysuria, drowsiness, dizziness, weight gain, 
excessive sweating and heart rhythm problems. A rare but potentially life-threatening 
adverse event is the serotonin syndrome whose symptoms include confusion, 
agitation, muscle twitching, sweating, shivering and diarrhoea. Rare, but serious cases 
may manifest with very high fever, epileptic fits, arrhythmia and coma. All classes of 
antidepressants have been linked to an increased risk of developing type 2 diabetes, 
but the causality is uncertain.  
There is a warning issued by the FDA (black box warning) concerning the risk of 
suicidality in pediatric patients taking SSRIs for depression (Libby et al., 2007) and a 
number of papers suggest that antidepressants are related to an increased risk for 
suicidal behaviour (Rouillon et al., 1991; Khan et al., 2000; Khan et al., 2001; Luoma 
et al., 2002; Baldessarini et al., 2003a; Healy, 2003; Khan et al., 2003) but not for 
completed suicide (Whittington et al., 2004). This might constitute one of the most 
interesting paradox of our contemporary psychiatry since antidepressants prevent 
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suicidal behaviour among severely ill, frequently suicidal ’real life’ unipolar 
depressives but may provoke such behaviour sometimes in less severe, actually 
nonsuicidal unipolar depressives (Leon et al., 1999; Angst et al., 2002; Yerevanian et 
al., 2004; Simon et al., 2006; Gibbons et al., 2007). It has been suggested that 
antidepressants induce suicidality essentially only in pseudo-unipolar patients 
(Akiskal and Benazzi, 2005; Rihmer and Akiskal, 2006; Perlis et al., 2007b)  while 
the data from the STAR*D trial suggest the presence of a genetic vulnerability 
predisposing to the manifestation of new suicidal ideation after antidepressant 
treatment (Laje et al., 2007; Perlis et al., 2007b; Perlis et al., 2007a).  
 
4.e. Switching to the opposite pole 
 
It is widely accepted among psychiatrists that both antidepressants and FGAs can 
induce a mood switch to the opposite pole, or a chronic, dysphoric, mixed or irritable 
state in BD patients and may accelerate episode frequency and/or may cause other 
forms of course destabilization in patients with BD. However, hard evidence is 
limited and the bulk of evidence comes from chart reviews and retrospective and open 
studies. A comprehensive summary of the risk to induce switching for all agents 
during the three phases of treatment is shown in table 10 
The literature suggests that without the concomitant use of an antimanic agent the 
switch rate to mania or hypomania is around 20-40% (Bottlender et al., 2001; 
Goldberg and Truman, 2003; Bottlender et al., 2004)  while with the concomintant 
use of an antimanic agent the rate is reduced to 14% or below (Nemeroff et al., 2001; 
Post et al., 2001; Post et al., 2006; Harel and Levkovitz, 2008; Licht et al., 2008; 
Tondo et al., 2010). More recent reports suggests that switching is exclusively related 
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to antidepressant monotherapy while the concomitant use of an antimanic agent has a 
robust protective effect (Viktorin et al., 2014). The results of the STEP-BD support 
the potentially harmful role of antidepressants in the long-term course of BD (Truman 
et al., 2007; El-Mallakh et al., 2008; El-Mallakh et al., 2015). According to that study 
switching to the opposite pole was not dose-dependent (Tada et al., 2015). However a 
number of larger RCTs reported negative data concerning  switching with paroxetine 
and bupropion (Sachs et al., 2007), fluoxetine, even as monotherapy in BD-II patients 
(Amsterdam et al., 2004), and citalopram (Schaffer et al., 2006). There are some data 
suggesting a higher risk of switching while on treatment with venlafaxine 
(Amsterdam and Garcia-Espana, 2000; Vieta et al., 2002; Altshuler et al., 2006; 
Leverich et al., 2006; Post et al., 2006; Altshuler et al., 2009) and imipramine  
(Himmelhoch et al., 1991; Nemeroff et al., 2001; Silverstone, 2001), but a more 
recent study reported that venlafaxine was equal to lithium and without any increase 
in the switch rate (Lorenzo-Luaces et al., 2016). 
It is important to mention that switching to mania or hypomania during treatment of 
comorbid OCD (White et al., 1986; Steiner, 1991; Vieta and Bernardo, 1992; Rihmer 
et al., 1996; Perugi et al., 2002) or panic disorder with antidepressants have been 
reported (Pecknold and Fleury, 1986; Sholomskas, 1990). 
The switch risk is probably as high as 18.2% in the short term and 35.6% during the 
continuation phase (Post et al., 2003) and is higher in BD-I patients in comparison to 
BD-II (14.2% vs. 7.1% in acute trials and 23.4% vs. 13.9% in maintenance studies). 
The rates of switching in unipolar patients are lower than those of bipolar (1.5% in 
acute trials and 6.0% in maintenance studies) (Bond et al., 2008; Tondo et al., 2010).   
Haloperidol and perphenazine treatment have been associated with the development 
of dysphoria and depression although the data are inconclusive for haloperidol (Tohen 
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et al., 2003b; Zarate and Tohen, 2004). On the contrary, SGAs do not appear to 
induce depression while some authors suggest they possess a mild protective property 
against switching (Tohen et al., 2003c; Amsterdam and Shults, 2005a; Calabrese et 
al., 2005b; Keck et al., 2005; Thase et al., 2006; Benazzi et al., 2009). A recent meta-
analysis reported that treating acute mania with SGAs is associated with a 42% lower 
risk of switch to depression than with haloperidol. Nevertheless, caution should be 
taken when considering this to be a class effect, as only olanzapine, quetiapine, and 
ziprasidone may show these advantages (Goikolea et al., 2013b). 
Overall there are no data to suggest a generalized and class effect for 
antidepressants or FGAs concerning the induction of an affective switch. There are 
negative data concerning all SSRIs and SGAs studied and positive data only 
concerning venlafaxine, imipramine and perphenazine. Some authors believe that at 
least, the switch risk, and perhaps also the risk for rapid cycling and new-onset 
suicidality have been over-interpreted (Grunze, 2008) and thus the issue of switching 
is still open and further research is needed. Also negative for the presence of a 
treatment-induced switch are the longitudinal data of Jules Angst (Angst, 1985). For a 
safe use of antidepressants in bipolar disorder, clinicians may follow the 
recommendations of the International Society for Bipolar Disorders Task Force 
(Pacchiarotti et al., 2013). 
 
5. Review of existing guidelines for BD 
 
A number of treatment guidelines were identified and their reference lists were 
utilized (APA, 1994, 1995; Suppes et al., 1995; Frances et al., 1996; 1997; AACAP, 
1997; Goodwin et al., 1997; Jobson, 1997; Kusumakar et al., 1997; McClellan and 
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Werry, 1997; Gilbert et al., 1998; Barreira et al., 1999; Bauer et al., 1999b; Rush et 
al., 1999; Dennehy, 2000; Goldberg, 2000; Sachs et al., 2000; Allen et al., 2001; 
Montgomery, 2001; Suppes et al., 2001; APA, 2002; Grunze et al., 2002; Suppes et 
al., 2002; Goodwin, 2003; Grunze et al., 2003; Licht et al., 2003; Rush et al., 2003; 
Suppes et al., 2003; Grunze et al., 2004; Hirschfeld, 2005; Yatham et al., 2005; 
National Collaborating Centre for Mental Health, 2006; O'Dowd, 2006; Yatham et al., 
2006; 2008; Nolen et al., 2008; Goodwin, 2009; Grunze et al., 2009; Jon et al., 2009; 
Ng et al., 2009; Yatham et al., 2009; Grunze et al., 2010; 2011; Beaulieu et al., 2012; 
Bond et al., 2012; McIntyre et al., 2012b; Rosenbluth et al., 2012; Schaffer et al., 
2012; Grunze et al., 2013; Yatham et al., 2013b; Yatham et al., 2013c; Mohammad 
and Osser, 2014; Malhi et al., 2015; Ostacher et al., 2015a; Woo et al., 2015; 
Goodwin et al., 2016). An additional source was the National Institute of Clinical 
Excellence (NICE) guideline concerning BD (NICE, 2014), while the latest version of 
the guidelines of the British Association of Psychopharmacology (Goodwin et al., 
2016) were included although they were published after the date of last literature 
search. 
A description of the most important and most recent guidelines (after 2005) will be 
included in the text that follows. In tables 17, 21 and 25 there is a detailed description 
of difference between the current CINP guidelines and previously developed 
guidelines by other bodies.  
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5.1. American Psychiatric Association Treatment Guidelines for BD 
 
In 2008 the APA developed a draft of new guidelines after a thorough review of the 
literature. However they were never published because of unresolved issues 
pertaining to the conflict of interest.  
 
5.2. The Canadian Network for Mood and Anxiety Treatments and International 
Society on Bipolar Disorder guidelines (CANMAT/ISBD)   
 
The most recent 2013 version of the CANMAT/ISBD guidelines (Yatham et al., 
2013c) suggest that for the treatment of acute manic episodes the first line 
recommendation is monotherapy with lithium, divalproex, divalproex ER, olanzapine, 
risperidone, quetiapine, quetiapine XR, aripiprazole, ziprasidone, asenapine or 
paliperidone ER and adjunctive therapy with risperidone, quetiapine, olanzapine, 
aripiprazole, asenapine on lithium or divalproex. The second line includes 
monotherapy with carbamazepine, carbamazepine ER, ECT or haloperidol and 
combination therapy with lithium plus divalproex. The third line of treatment includes 
monotherapy with chlorpromazine, clozapine, oxcarbazepine, tamoxifen or 
cariprazine and combination therapy with lithium or divalproex plus haloperidol, 
lithium plus carbamazepine or adjunctive tamoxifen. They do not recommend 
monotherapy with gabapentin, topiramate, lamotrigine, verapamil, tiagabine and 
combination therapy with risperidone or olanzapine plus carbamazepine.  
For the treatment of acute BD-I depression as first line option they recommend 
monotherapy with lithium, lamotrigine, quetiapine or quetiapine XR and combination 
therapy with lithium or divalproex or olanzapine plus an SSRI, lithium plus 
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divalproex and lithium or divalproex plus bupropion. The second line includes 
monotherapy with divalproex or lurasidone and combination therapy with quetiapine 
plus an SSRI, adjunctive modafinil and lithium or divalproex plus lamotrigine or 
lurasidone. The third line includes monotherapy with carbamazepine, olanzapine or 
ECT or combination therapy with lithium plus carbamazepine or pramipexole, lithium 
or divalproex plus venlafaxine, lithium plus MAOI, lithium or divalproex or atypical 
antipsychotic plus a TCA, lithium or divalproex or carbamazepine plus an SSRI plus 
lamotrigine and quetiapine plus lamotrigine. They do not recommend monotherapy 
with gabapentin, aripiprazole or ziprasidone and combination therapy with adjunctive 
ziprasidone or levetiracetam. 
For the maintenance treatment, the first line recommendation includes monotherapy 
with lithium, lamotrigine, divalproex, olanzapine, quetiapine, risperidone LAI and 
aripiprazole and adjunctive therapy with quetiapine, risperidone LAI, aripiprazole or 
ziprasidone on lithium or divalproex. The second line monotherapy includes 
carbamazepine and paliperidone ER and combination therapy with lithium plus 
divalproex or carbamazepine, lithium or divalproex plus olanzapine, risperidone or 
lamotrigine and olanzapine plus fluoxetine. The third line monotherapy includes 
asenapine and the adjunctive therapy includes phenytoin, clozapine, ECT, topiramate, 
omega-3-fatty acids, oxcarbazepine, gabapentin and asenapine. They do not 
recommend monotherapy with gabapentin, topiramate, or antidepressants and 
adjunctive therapy with flupenthixol. 
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5.3. The World Federation of Societies of Biological Psychiatry (WFSBP) 
guidelines for the biological treatment of BD. 
 
The latest WFSBP guidelines utilized a modified version of the PORT method to 
grade the data concerning efficacy (Grunze et al., 2009; Grunze et al., 2010, 2013) 
and afterwards utilized a secondary classification to include also safety and 
tolerability. 
For the treatment of acute mania, as first choice agents are ranked aripiprazole, 
valproate, risperidone and ziprasidone. As second choice olanzapine, quetiapine, 
asenapine, carbamazepine, haloperidol, and lithium were recommended. The third 
choice includes chlorpromazine, paliperidone, phenytoin, pimozide and tamoxifen. 
The fourth includes amisulpride, clonazepam, clozapine, levetiracetam, lorazepam, 
nimodipine, oxcarbazepine, retigabine, zonisamide, zotepine and ECT. The fifth and 
final choice includes verapamil. With the utilization of this classification, the WFSBP 
suggests that concerning the treatment of acute mania the first step includes 
monotherapy with first choice agents. The second step would be the switching to 
another first choice agent or combine two first choice agents. Similarly the third step 
includes combination of two first choice agents. The fourth and fifth steps include 
combinations of agents essentially according to the judgement of the therapist.  
For the treatment of acute bipolar depression, the WFSBP guidelines suggest that first 
choice agent is only quetiapine while there next best option includes olanzapine, 
fluoxetine, lamotrigine, valproate, OFC, lithium plus lamotrigine, adjunctive 
modafinil, N-acetylcysteine on lithium or valproate and FEWP plus carbamazepine. A 
variety of combinations are proposed as next steps. 
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For the treatment during the maintenance phase the guidance is more complex and on 
the basis of the available data the WFSBP guidelines suggest the use of aripiprazole, 
lamotrigine, lithium, quetiapine, olanzapine and risperidone but they note that not all 
of them prevent both mania and depression. They also note the problems because of 
the metabolic syndrome induced by some of these agents when used for prolonged 
periods of time. They also suggest the avoidance of typical antipsychotics because of 
the risk to induce tardive dyskinesia. 
 
5.4. British Association for Psychopharmacology (BAP) 
 
The 2016 BAP guidelines for the treatment of BD (Goodwin et al., 2016) recommend 
for acute mania antidopaminergic agents, lithium or valproate. For acute bipolar 
depression they recommend quetiapine, olanzapine, olanzapine plus fluoxetine, 
antidepressants, lurasidone and lamotrigine as combination. It also recommends 
family focused therapy, IPSRT and CBT as add-on to medication but also CBT as 
monotherapy as an extrapolation of unipolar depression studies. For the maintenance 
phase they recommend lithium (for mania, depression and suicide), dopamine 
antagonists and partial agonists as well as valproate (mainly for mania), lamotrigine 
(for depression) and Family focused therapy, CBT and IPSRT as add-on to 
medication  
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5.5. The UK National Institute of Clinical Excellence (NICE) treatment 
guidelines for BD (NICE, 2014). 
 
Concerning acute mania, the 2014 NICE guidelines recommend the use of olanzapine, 
risperidone, quetiapine or haloperidol. If the patient does not respond it is 
recommended to change to another antipsychotic and the choice should be made also 
on the basis of previous response if it exists. If the patient is already under treatment 
with lithium or valproate then the recommendation is to increase dosage to the highest 
permitted and reassessment should follow before the changing of medication. If an 
antidepressant is in place, it should be discontinued. The second step includes 
combination of lithium or valproate plus an antipsychotic and the third step demands 
hospitalization. The NICE warns against the use of gabapentin, lamotrigine and 
topiramate in acute mania. 
For acute bipolar depression, the NICE recommends olanzapine, OFC, quetiapine, 
lamotrigine, lithium and valproate. If the patient is already under treatment with 
lithium or valproate then the recommendation is to increase the dosage to the highest 
permitted and reassessment should follow before the changing of medication. The 
next step includes combination of lithium or valproate plus quetiapine or OFC. The 
third step includes lithium plus lamotrigine or olanzapine and valproate plus 
lamotrigine. The NICE warns against the use of gabapentin and topiramate. 
During the maintenance phase, the NICE guidelines recommend as first line treatment 
the continuation of the treatment the patient received during the acute phase and led to 
the resolution of the symptoms. Irrespective of predominant polarity the continuation 
of this treatment should be done for at least 3-6 months. In case the patient does not 
wish to follow this, it is recommended to change treatment to lithium, olanzapine, 
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quetiapine, valproate or lithium plus valproate. Again, NICE warns against the use of 
gabapentin and topiramate. 
The procedure and the interpretation of evidence as presented in the NICE guidelines 
have been criticized (Jauhar et al., 2016). 
 
6. Efficay, recommendation level and precise treatment algorithm 
 
The detailed table of the efficacy level for all treatment options during all phases and 
against specific features of BD is shown in webappendix 1. The detailed table of the 
recommendation level for all treatment options during all phases and against specific 
features of BD is shown in webappendix 2. Add-on and combination data were 
merged for the sake of simplicity. Additionally, the detailed precise algorithm which 
was developed is shown in webappendix 3.  
The levels of recommendation concerning monotherapy in acute mania and 
recommended dosages for medication options are shown in table 11, while the 
recommendation levels for combination treatment are shown in table 12. 
Recommendation levels concerning treatment options for rapid cycling patients are 
shown in table 13 and the effects on concomitant depressive and psychotic features 
are shown in table 14. The recommendation levels for monotherapy and combination 
treatment in patients with a DSM-IV-TR mixed episode and the specific effects on the 
manic and the depressive component are shown in table 15 (provided here for 
academic reasons).  
The chart of the algorithm for acute mania/hypomania on the basis of strict evidence 
and by taking into consideration specific clinical features is shown in table 16. The 
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comparison of this algorithm to previously developed guidelines for acute mania is 
shown in table 17. 
The levels of recommendation concerning monotherapy in acute bipolar depression, 
in comorbid conditions and rapid cycling patients and recommended dosages for 
medication options are shown in table 18, while the levels of recommendation 
concerning combination treatment are shown in table 19.  
The chart of the algorithm for acute bipolar depression is shown in table 20. The 
comparison of this algorithm to previously developed guidelines for acute bipolar 
depression is shown in table 21. 
The levels of recommendation concerning monotherapy during the maintenance phase 
and in relationship to index episode, composition of the sample, presence of rapid 
cycling and the efficacy in the prevention of manic, mixed or depressive episodes as 
well as recommended dosages are shown in table 22, while the levels of 
recommendation concerning combination treatment during the maintenance phase are 
shown in table 23. 
The chart of the algorithm for the maintenance phase is shown in table 24. The 
comparison of this algorithm to previously developed guidelines for the maintenance 
phase is shown in table 25. 
Overall the algorithm consists of the stepwise approach in tables 16, 20 and 24 and in 
web appendix 3. However, a more fundamental approach would be to utilize web 
appendix 2 which includes a table with the recommendation levels by clinical 
indication for all the treatment options. The utilization of this table could be more 
precise and accurate in comparison to the stepwise description. Until then, the 
clinician can handle the table in a manual way.  First he should decide on the phase of 
the disorder (acute manic vs. mixed vs. depressive episode vs. maintenance phase). 
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Then he should choose the combination of the clinical features under the specific 
phase and finally he will identify which treatment options best fit the clinical 
syndrome. For example if the patient is in an acute manic episode with some 
accompanying depressive symptoms (mixed features) and psychotic symptoms and 
his history suggests he is also a rapid cycling, then the only agents which treats all 
these conditions are olanzapine and quetiapine followed by lithium which is second 
choice. If the patient is BD-II in a depressive episode with anxiety, then the only 
suitable agent is quetiapine. Of course such an algorithm might be too restrictive; 
however, the clinician can use the table to produce combinations of treatment options 
to satisfy all clinical needs on the basis on research data. 
 
7. Discussion 
 
The current paper represents a systematic search of the literature on the treatment of 
BD. By using an established approach we identified all relevant RCTs pertaining all 
faces and special issues of BD and graded the data according to a pre-determined 
method. Finally, a recommendation level was assigned to all treatment options 
depending on the clinical situation. 
It was interesting to see that except of rare cases, the concept of ‘mood stabilizers’ is 
not supported by the available data, especially for those agents traditionally 
considered as such. 
It is obvious that, by far, the body of evidence originates from RCTs which were 
conducted with agents which have been launched in the last two decades. This 
constitutes a significant bias in the literature and one should be cautious in the way 
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that the accumulated clinical experience concerning those agents and treatment 
modalities with poor evidence based support should also be taken into account.  
A low grade of evidence for these old and poorly studied agents and modalities (e.g  
carbamazepine, clozapine, ECT etc.) does not necessarily mean a lower effectiveness 
and safety in comparison with other drugs, but it still implies that the clinicians should 
be cautious in their application in patients with BD. On the other hand it is  irrational 
to use different standards; on the one hand to study carefully and seek flaws in the 
design of major RCTs and on the other hand to accept a wide recommendation of 
agents with poor evidence based support because of historical reasons. The authors of 
the current paper spend much time and effort to grade the agents on the basis of 
quantitative but also qualitative characteristics of the data available. This effort 
resulted in the development of a precise algorithm on the basis of a reproducible 
methodology.  
Also, the results on those areas of interest which are not targeted as primary outcomes 
are reported in a non-systematic way and therefore the grading of evidence is lower. 
Unfortunately these areas constitute the overwhelming clinical picture of BD.  
As with many other guidelines, the inherent limitations of the literature as well as the 
unavoidable subjectivity of experts when making a recommendation (even when 
based on evidence) should be taken seriously into consideration by the clinicians 
when reading the current paper. Also negative results (level 5) should be taken very 
seriously into consideration, as they should be considered to be scientifically stronger 
in comparison to positive ones. 
Further limitations include the heterogeneity of the RCTs that served as basis for the 
recommendations and the lack of trials assessing specific subpopulations, following 
the rules of stratified medicine (Schumann et al., 2014), or applying staging methods 
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to psychopharmacology (Grande et al., 2015), in search of more precision when 
treating individual patients (Vieta, 2015). However, these CINP guidelines represent 
the most up-to-date effort to condense the current knowledge on the management of 
bipolar disorder from an international perspective. 
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Figure 1: PRISMA flowchart for RCTs literature search 
 
Figure 1: PRISMA flowchart for treatment guidelines literature search 
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Grading on basis of efficacy 
 
Level 1 Good research-based evidence, supported by at least 2 placebo controlled studies of 
sufficient magnitude and good quality. In case of the presence of negative RCTs, positive 
RCTs should outnumber negative ones 
 
Level 2 Fair research-based evidence, from one randomised, double-blind placebo controlled 
trial.  
Also in case one or more trials exist, however, they fail to fulfil all the criteria above 
(e.g., very small sample size or no placebo control) as well as in case of positive meta-
analysis alone. 
 
Level 3 Some evidence from comparative studies without placebo arm or from post-hoc analyses. 
 
Level 4 Inconclusive data or poor quality of RCTs 
 
Level 5 Negative data 
 
 
Grading on the basis of safety and tolerability 
 
Level 1 Very good tolerability, few side effects which are not enduring, they do not cause 
significant distress and are not life-threatening and they do not compromise the overall 
somatic health of the patient 
 
 
Level 2 Moderate tolerability, many side effects which could be enduring, and cause significant 
distress but they are not life-threatening although they could compromise the overall 
somatic health of the patient.  
Agents with very good overall tolerability but with rare life-threatening adverse events, 
could be classified here only if the lethality risk can be essentially considered to be 
negligible with the application of procedures and protocols (e.g. laboratory testing, 
titration schedules etc.) 
 
 
Level 3 Poor tolerability, many side effects which are enduring, cause significant distress, 
compromise the overall somatic health of the patient or are life-threatening. 
Agents with moderate overall tolerability and rare life-threatening adverse events should 
be classified here even in cases the lethality risk can be essentially considered to be 
negligible with the application of procedures and protocols (e.g. laboratory testing, 
titration schedules etc.) 
 
 
Recommendations for treatment (combination of efficacy and safety/tolerability) 
 
Level 1 Level 1 or 2 for efficacy and 1 for safety/tolerability 
 
Level 2 Level 1 or 2 for efficacy and 2 for safety/tolerability 
 
Level 3 Level 3 for efficacy and 1 or 2 for safety/tolerability 
 
Level 4 Level 4 for efficacy or 3 for safety/tolerability 
 
Level 5 Level 5 for efficacy (not recommended) 
 
 
Table 1: The method for the grading of data, on the basis of efficacy and tolerability. 
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 Acute manic episodes  
Agent/modality 
(alphabetical order) 
Effect  
start  
day 
Monotherapy  Combination with: 
  overall Core 
manic 
Depres
sive  
Psycho
tic  
agita
tion 
MS Cbz Lam Li Val FGAs 
Allopurinol - - - - - - 5 - - 3 - 5 
Aripiprazole 2-4 1 - 5 3 - 2 - - - - - 
Asenapine 2 1 - 4 - - 2 - - - - - 
Carbamazepine 14 1 - 5 - - - - - - - - 
Cariprazine  4 1 3 5 - - - - - - - - 
Celecoxib    - - - - - - - - - - 2 - 
Chlorpromazine - 4 - - - - - - - - - - 
Clozapine  - - - - - - - - - - - - 
ECT - 3 - - - - - - - - - - 
Eslicarbazepine  - 5 - - - - - - - - - - 
Gabapentin - 5 - - - - 5 - - - - - 
Haloperidol 4 1 5 5 3 3 2 2 - 2 2 - 
Lamotrigine - 5 - - - - - - - - - - 
Levetiracetam  - - - - - - - - - - - - 
Licarbazepine  - 5 - - - - - - - - - - 
Lithium 7 1 4 5 2 - - 2 - - - - 
Loxapine inhalant - - - - - 2 - - - - - - 
Medroxyprogesterone    - - - - - - 5 - - - - - 
Olanzapine 2-7 1 3 3 3 2 1 5 - - 1 - 
Oxcarbazepine - 4 - - - - - - - 4 - - 
Paliperidone 2 1 - - - - 5 - - - - - 
Pimozide - 4 - - - - - - - - - - 
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Quetiapine 4 1 - 3 3 - 3 - - 2 - - 
Risperidone 3 1 - 3 3 - 3 - - - 5 - 
Tamoxifen 5 2 3 5 3 - 2 - - 2 - - 
TMS - 5 - - - - - - - - - - 
Topiramate - 5 - - - - 5 - - - - - 
Valproate 5-15 1 5 5 - 3 - - - - - 2 
Verapamil - 5 - - - - - - - - - - 
Ziprasidone 2 1 3 5 3 - 5 - - - - - 
 
Table 2: Acute mania/mixed treatment phase, grading on basis of efficacy (treatment phase up to 12 weeks). The treatment options are rated 
according to the rating system shown in table 1 
- : no data 
Cbz: Carbamazepine 
ECT: Electroconvulsive therapy 
FGAs: First Generation Antipsychotics 
Lam: Lamotrigine 
Li: Lithium 
MS: Mood Stabilizer 
TMS: Transcranial Magnetic Stimulation 
Val: Valproate 
  
 by guest on N
ovem
ber 17, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pt
ed
 M
an
us
cr
ipt
 105 
 
  Monotherapy combination Anxiety 
agent/modality  
(alphabetical order) 
overall  BD-I BD-II 
depressive 
core 
MS Cbz Lam Li Val   
Agomelatine - - - - 5 - - 5 5 - 
Aripiprazole 3 3 - - - - - 5 - - 
Armodafinil  - - - - 4 - - - - - 
Bupropion - - - - 5 - - - - - 
Carbamazepine 3 - - - - - - - - - 
Celecoxib   - - - - 5 - - - - - 
Donepezil 5 - - - - - - 5 - - 
Escitalopram - - 2 - - - - - - - 
Fluoxetine 2 - 3 - - - - 4 - - 
FEWP - - - - - 4 - - - - 
Gabapentin 5 - - - - - - - - - 
Imipramine  3 - - - - - - 5 - - 
Ketamine  - - - - 2 - - - - - 
Lamotrigine 3 3 3 3 - - - 2 - - 
Levetiracetam  - - - - 5 - - - - - 
Levothyroxine (L-T4) - - - - 4 - - - - - 
Lisdexamfetamine  - - - - 5 - - - - - 
Lithium 4 - - - - - 2 - - 5 
L-sulpiride  - - - - - - - 3 - - 
Lurasidone 2 2 - 3 2 - - - - 3 
memantine - - - - - - 5 - - - 
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modafinil - - - - 2 - - - - - 
OFC 2 2 - 3 - - - - - - 
Olanzapine 1 1 - 3 - - - - - - 
Oxcarbazepine - - - - - - - 4 - - 
Paroxetine 5 5 5 - 5 Neg  - 5 5  3 
Phenelzin  3 - - - - - - - - - 
Pioglitazone  - - - - - - - 2 - - 
Pramipexole - - - - 2 - - - - - 
Pregnenolone  - - - - 5 - - - - - 
Quetiapine 1 3 3 3 - - - - - 3 
Risperidone - - - - 5 - - - - 5 
TMS 5 - - - - - - - - - 
tranylcypromine  4 4 4 - - - - - - - 
Valproate 3 3 5 3 - - - - - 3 
Venlafaxine  4 4 4 - - - - - - - 
Ziprasidone 5 5 - - 5 - 5 5 5 5 
 
 
Table 3: Acute depression treatment phase, grading on basis of efficacy (treatment phase up to 12 weeks). The treatment options are rated 
according to the rating system shown in table 1 
- : no data 
Cbz: Carbamazepine 
ECT: Electroconvulsive therapy 
FEWP: Free and Easy Wanderer Plus 
Lam: Lamotrigine 
Li: Lithium 
MS: Mood Stabilizer 
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OFC: Olanzapine Fluoxetine Combination 
TMS: Transcranial Magnetic Stimulation 
Val: Valproate 
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agent/modality  
(alphabetical order) 
index episode Enriched sample 
Any 
episode 
Manic  Depressive 
Aripiprazole m* yes - 1 5 
Carbamazepine - - 4 4 4 
Fluoxetine d Yes  - - 2 
Imipramine  d ? 5 5 5 
Lamotrigine m/d yes  1 3 1 
Lithium m/d No 1 1 3 
Olanzapine m Yes/No 1 1 1 
Paliperidone m yes  1 2 5 
Quetiapine m/d yes 2 2 2 
Risperidone, LAI m yes 1 1 5 
Valproate m yes 4 4 3 
 
Table 4: Monotherapy treatment during the maintenance phase, grading on basis of 
efficacy. The treatment options are rated according to the rating system shown in table 
1 
Enriched sample: the sample is enriched on the basis of remission after treatment with 
the agent under consideration during the acute phase (index episode) 
- : no data 
m: mania/mixed, d: depression, m/d: both mania and depression 
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   overall manic depressive 
agent/modality (alphabetical order) 
index 
episode 
Enriched 
sample 
MS Lam Li Val MS Lam Li MS Lam Li Val 
Aripiprazole m* yes 2 5 - 5 2 5 - 5 5 - - 
CBT d No 2 - - - - - - - - - - 
Gabapentin - - - - - - 4 - - - - - - 
Imipramine  d ? - - 5 
 
- - - - - - - 
Lamotrigine m/d yes  - - 4 
 
- - - - - - 5 
Lithium m/d No - 4 - - - - - - - - - 
Memantine - - - - - 5 - - - - - - - 
N-acetyl cysteine d Yes  4 - - - - - - - - - - 
Olanzapine m Yes/No 4 - - - - - - - - - - 
Oxcarbazepine - - - - 5 - - - 5 - - 5 - 
Paroxetine - - 3 - - - - - - 3 - - - 
Perphenazine  m yes  5 - - - - - - - - - - 
Phenytoin  euth No 2 - - - - - - - - - - 
Quetiapine m/d yes 1 - - - 1 - - 1 - - - 
Risperidone, Long-acting Injectable  m yes 2 - - - 2 - - - - - - 
Valproate m yes - - - - - - - - 5 - - 
Ziprasidone m yes 2 - - - - - - - - - - 
 
Table 5: Combination treatment during the maintenance phase, grading on basis of efficacy. The treatment options are rated according to the 
rating system shown in table 1. 
Enriched sample: the sample is enriched on the basis of remission after treatment with the agent under consideration during the acute phase 
(index episode) 
- : no data      m: mania/mixed, d: depression, m/d: both mania and depression 
 by guest on N
ovem
ber 17, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pt
ed
 M
an
us
cr
ipt
 110 
CBT: Cognitive Behavioural Therapy 
Cbz: Carbamazepine 
Lam: Lamotrigine 
Li: Lithium 
MS: Mood Stabilizer 
Val: Valproate 
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  Acute phase Maintenance phase 
  Monotherapy  Combination with MS  Monotherapy  Combination   
agent/modality  
(alphabetical order) 
manic 
component 
Depressive  
component 
Manic 
component 
Depressive  
component 
 MS Cbz Lam Li Val 
Aripiprazole 3 3 - - - 2 - 5 - - 
Asenapine 4 4 - - - - - - - - 
Carbamazepine 3 3 - - - - - - - - 
Celecoxib   - - 5 5 - - - - - - 
Haloperidol  - - 5 5 - - - - - - 
Lithium 5 - - - - - - - - - 
OFC 4 4 - - - - - - - - 
Olanzapine 3 3 2 2 1 - - - - - 
Paliperidone 3 5 - - - - - - - - 
Quetiapine 5 - - - - - - - - - 
Risperidone 3 - 5 5 - - - - - - 
Valproate 3 4 - - - - - - - - 
Ziprasidone 4 4 - - - - - - - - 
 
Table 6: Treatment of mixed episodes. The treatment options are rated on the basis of efficacy according to the rating system shown in table 1 
- : no data 
Cbz: Carbamazepine             Lam: Lamotrigine    Li: Lithium     MS: Mood Stabilizer   OFC: Olanzapine-Fluoxetine Combination  
Val: Valproate 
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agent/modality (alphabetical order) acute mania depression maintenance 
Aripiprazole 3 - 3 
Carbamazepine - - 2 (Li + Cbz)  
Lamotrigine - - 5 
Lithium 4 3 2 (Li, Li + Cbz) 
Olanzapine 3 - - 
Paroxetine - 5 - 
Quetiapine 3 2 2 (Quet+ Val/Li) 
Risperidone, Long-acting Injectable  - - 2 (RLAI+TAU) 
Valproate 4 4 - 
 
Table 7: Treatment of rapid cycling patients during the different phases of BD. The 
treatment options are rated on the basis of efficacy according to the rating system 
shown in table 1 
- : no data 
Cbz: Carbamazepine 
Li: Lithium 
Quet: Quetiapine 
RLAI: Risperidone Long-acting Injectable 
TAU: Treatment As Usual 
Val: Valproate 
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Intervention  Efficacy 
 Relapse/ 
recurrence 
Manic 
symptoms 
Depressive 
symptoms 
Anxiety Neurocognition Overall 
functioning 
CBT 5 - 3 - - - 
Psychoeducation 3 5 5 - - 3 
IPSRT 4 - - - - - 
Family intervention 5 5 5 - - 5 
Intensive psychosocial intervention  - - - - - - 
Cognitive remediation 5 5 5 - 5 5 
Mindfulness based interventions 5 5 5 3 - - 
 
Table 8:  Grading of the evidence for the efficacy of non-biological treatment options. The treatment options are rated according to the rating 
system shown in table 1 
- : no data 
CBT: Cognitive Behavioral Treatment 
IPSRT: InterPersonal and Social Rhythms Therapy 
 
 
 by guest on N
ovem
ber 17, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pt
ed
 M
an
us
cr
ipt
114 
 
 
 
agent/modality  
(alphabetical order) 
grade comments 
Agomelatine 2 Liver enzymes induction 
Allopurinol  2 Swelling of mouth and lips, severe skin rashes, infections, eye 
irritation, hepatitis, appetite and weight loss, and painful or bloody 
urination 
Aripiprazole 1  
Armodafinil/modafinil  2 Stimulant, risk for abuse 
Asenapine 1  
Bupropion 1  
Carbamazepine 2 Hepatic enzymes induction, many adverse effects 
Cariprazine  1  
Celecoxib 1  
Chlorpromazine 1  
Clozapine  3 Potentially lethal agranulocytosis, metabolic syndrome 
Donepezil 1  
ECT 2 Not preferred by patients, mild cognitive problems 
Escitalopram 1  
Eslicarbazepine  1  
Fluoxetine 1  
FEWP 1  
Gabapentin 1  
Haloperidol 2 EPS, Tardive dyskinesia, neuroleptic malignant syndrome, switch risk 
Imipramine  2 Cardiac side effects, many adverse effects, switch risk 
Ketamine  3 Stimulant 
L-sulpiride  1  
Lamotrigine 2 Good overall tolerability but potentially lethal skin reaction which can 
be avoided by slow titration 
Levetiracetam  3 Induction of suicidality 
levothyroxine (L-T4) 2 Mild cardiovascular, skin and bone adverse effects 
Licarbazepine  1  
Lisdexamfetamine  3 High risk for abuse and dependence 
Lithium 2 Many adverse effects, weight gain, toxicity 
Loxapine inhalant 1  
Lurasidone 1  
N-acetyl cysteine 1  
Memantine  1  
Medroxyprogesterone    1  
Modafinil  2 Stimulant, risk for abuse 
Olanzapine 2 Metabolic syndrome 
Oxcarbazepine 1  
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Paliperidone 1  
Paroxetine 1  
Perphenazine  2 Switch risk, EPS, tardive dyskinesia, neuroleptic malignant syndrome 
Phenytoin  2 Many adverse effects 
Phenelzin   2 Many adverse effects 
Pimozide 2 EPS, tardive dyskinesia, neuroleptic malignant syndrome 
Pioglitazone  2 Not recommended in patients with diabetes mellitus type I and in liver 
disease. Absolute contraindication in heart failure patients 
Pramipexole  2 Adverse effects include the induction of problematic behaviours and 
psychotic symptoms 
Pregnenolone  2 Not well studied 
Quetiapine 1  
Risperidone 1  
RLAI 1  
Sertraline  1  
Tamoxifen 3 Deep vein thrombosis, cognitive disorder 
TMS 1  
Topiramate 3 Induction of depression and suicidality 
Tranylcypromine   2 Many adverse effects 
Valproate 1 Cautious use in women of childbearing age 
Venlafaxine  2 Switch risk 
Verapamil  1  
Ziprasidone 2 QTc prolongation, patients should undergo cardiologic examination 
before receiving ziprasidone 
 
Table 9: Grading of treatment options according to safety issues, according to the 
system shown in table 1. 
ECT: Electroconvulsive Therapy 
EPS: Extrapyramidal Signs 
FEWP: Free and Easy Wanderer Plus 
RLAI: Risperidone Long-acting Injectable 
TMS: Transcranial Magnetic Stimulation 
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 Treatment phase 
agent/modality (alphabetical order) Acute mania depression maintenance 
Aripiprazole 5 5 5 
Asenapine 5 - 5 
Bupropion - 5 - 
Carbamazepine 5 - 5 
ECT - 4 - 
Escitalopram - 5 - 
Fluoxetine - - 5 
Haloperidol 4 - 4 
Imipramine  - 3 2 
Lamotrigine 5 - 5 
Lithium 5 - 5 
OFC - 5 5 
Olanzapine 5 5 5 
Paliperidone 5 - 5 
Paroxetine - 5 5 
Perphenazine  4 - 2 
Quetiapine 5 5 5 
RLAI 5 - 5 
Sertraline  - - 5 
Valproate 5 - 5 
Venlafaxine  - 3 - 
Ziprasidone 5 - 5 
 
Table 10: Risk of various agents to induce the opposite mood pole (switch risk). The 
treatment options are rated in an analogous way to the rating system shown in table 1 
as ‘efficacy to induce the opposite pole’ 
- : no data 
ECT: Electroconvulsive Therapy 
OFC: Olanzapine-fluoxetine combination 
RLAI: Risperidone Long-acting Injectable 
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agent/modality  
Recommendation 
level 
Recommended dosage (mg/day) 
Aripiprazole 1 15-30  mg/day 
Asenapine 1 10-20 mg/day 
Cariprazine  1  3-12 mg/day 
Paliperidone 1  3-12 mg/day 
Quetiapine 1 400-800 mg/day 
Risperidone 1 2-6 mg/day 
Valproate 1 
1200-3000 mg/day (loading  dose 20-30 mg/kg body 
weight; serum  level 75-150 mg)  
Carbamazepine 2 600-1200 mg/day (serum  level 4-15 mg/l) 
Haloperidol 2 5-20 mg/day 
Lithium 2 600-1200 mg/day (serum  level 0.8-1.3 mmol) 
Olanzapine 2 10-20 mg/day 
ECT 3   
Oxcarbazepine 4  900-1800 mg/day 
Chlorpromazine 4  300-1000 mg/day 
Pimozide 4  2-16 mg/day 
Tamoxifen 4  40-80 mg/day 
Ziprasidone 4 80-160 mg/day` 
Eslicarbazepine  5  
Gabapentin 5  
Lamotrigine 5  
Licarbazepine  5  
TMS 5  
Topiramate 5  
Verapamil 5   
 
Table 11: Levels of recommendation concerning monotherapy in acute mania and 
recommended dosages for medication options 
NR: not recommended 
ECT: Electroconvulsive therapy 
TMS: Transcranial Magnetic Stimulation 
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agent/modality MS Li Val Cbz FGAs 
Asenapine 1 - - - - 
Haloperidol 2 2 2 2 - 
Olanzapine 2 - 2 5 - 
Aripiprazole 2 - - - - 
Medroxyprogesterone    5 - - - - 
Celecoxib - - 2 - - 
Quetiapine 3 3 - - - 
Risperidone 3 - 5 - - 
Tamoxifen 4 4 - - - 
Allopurinol 5 2 - - 5 
Paliperidone 5 - - - - 
Ziprasidone 5 - - - - 
Gabapentin 5 - - - - 
Topiramate 5 - - - - 
Lamotrigine - - - - - 
Lithium - - - 2 - 
Oxcarbazepine - 4 - - - 
Valproate - - - - 2 
 
Table 12: Recommendation levels for combination treatment for acute mania 
MS: mood stabilizer 
Li: lithium, Val: valproate, Cbz: carbamazepine, FGAs: first generation antipsychotics 
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agent/modality 
Recommendation 
level 
Quetiapine 3 
Aripiprazole 3 
Olanzapine 3 
Valproate 4 
Lithium 4 
 
Table 13: Recommendation levels for monotherapy in rapid cycling patients in an 
acute manic episode 
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agent/modality Therapeutic effect on 
 
Overall on  
manic episode 
Concomitant Depressive 
symptoms  
Psychotic 
symptoms  
Quetiapine 1 3 3 
Risperidone 1 3 3 
Aripiprazole 1 5 3 
Asenapine 1 5 - 
Olanzapine 2 3 3 
Carbamazepine 2 5 - 
Cariprazine  1 5 - 
Haloperidol 2 5 3 
Lithium 2 5 3 
Tamoxifen 4 5 4 
Valproate 1 5 - 
Ziprasidone 2 5 3 
 
Table 14: Recommendation levels for monotherapy in patients in an acute manic 
episode and the specific effect on concomitant depressive symptoms (mixed features) 
and psychotic features. 
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  monotherapy combination with MS 
agent/modality  
manic 
component 
Depressive 
component 
manic 
component 
Depressive 
component 
Olanzapine 3 3 2 2 
Asenapine  3 3 - - 
Aripiprazole 3 3 - - 
Carbamazepine 3 3 - - 
Valproate 3 4 - - 
Paliperidone 3 5 - - 
Risperidone 3 - 5 5 
OFC 4 4 - - 
Ziprasidone 4 4 - - 
Lithium 5 - - - 
Quetiapine 5 - - - 
Celecoxib   - - 5 5 
Haloperidol - - 5 5 
 
Table 15: Recommendation levels for monotherapy and combination treatment in 
patients in a DSM-IV-TR mixed episode and the specific effect on the manic and the 
depressive component. 
MS: mood stabilizer 
OFC: olanzapine-fluoxetine combination 
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Step First  Second  Third  Fourth  Fifth  
All cases Discontinue treatment with antidepressants 
Rapid cycling 
Start with aripiprazole or quetiapine monotherapy.  
In non-psychotic cases valproate is also an option 
Take into consideration the previous history of 
psychotic features. 
Olanzapine or lithium monotherapy 
Combination 
treatment of 
lithium or 
valproate with 
quetiapine, or 
risperidone.  
 
Apply ECT on top of 
pharmacological 
treatment.  
 
Monotherapy with 
chlorpromazine, 
pimozide,  or 
tamoxifen.  
Options are also 
combination 
treatments of lithium 
or valproate plus 
tamoxifen or the 
combination of 
risperidone or 
oxcarbazepine plus 
lithium 
Various combinations 
of medication 
according to anecdotal 
knowledge or the 
personal experience of 
the therapist, ECT if 
not applied earlier 
 
Non- 
Rapid cycling 
with psychotic 
features 
Start with aripiprazole, cariprazine, paliperidone, 
quetiapine or risperidone monotherapy.  
 
Monotherapy with haloperidol, lithium, 
olanzapine or ziprasidone or combination 
treatment of lithium or valproate with 
aripiprazole, haloperidol or olanzapine. 
Lithium combinations with allopurinol* is 
also an option. Another combination is 
valproate plus an FGA.  
Non rapid 
cycling without 
Psychotic  
features 
All options which are suitable in the presence of 
psychotic features and also valproate and asenapine 
monotherapy are a choice.  
Take into consideration the previous history of 
psychotic features. 
 
All options which are suitable in the 
presence of psychotic features and also 
monotherapy with carbamazepine or 
valproate plus celecoxib* are an option 
Take into consideration the previous 
history of psychotic features. 
Mixed  
Features 
Start with quetiapine or risperidone monotherapy. Olanzapine monotherapy 
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All other cases 
If the patient is already under one of the above ‘first 
step’ monotherapy or under combination therapy of 
any kind and response is unsatisfactory, switch into 
another ‘first step’ monotherapy. 
In case the personal history of the patient suggests 
this is not an option, proceed to next step and switch 
to the closest second step treatment option.  
Proceed to next step 
Mixed episode 
Start with combination of olanzapine plus valproate 
or maybe lithium  
Monotherapy with olanzapine, 
aripiprazole or carbamazepine.  
Valproate 
monotherapy  
OFC or ziprasidone 
monotherapy.  
 
 
Table 16: Precise evidence-based alrogithm to treat acute manic episodes on the basis of specific clinical characteristics 
*  no wide clinical experience   
 
CBT: Cognitive Behavioral Treatment 
Cbz: Carbamazepine 
ECT: Electroconvulsive therapy 
IPSRT: InterPersonal and Social Rhythms Therapy 
Lam: Lamotrigine 
Li: Lithium 
MS: Mood Stabilizer 
OFC: Olanzapine Fluoxetine Combination 
rTMS: repetitive Transcranial Magnetic Stimulation 
Val: Valproate 
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CINP 
2016 
WFSBP 
2013* 
CANMAT  
& 
ISBD 2013 
NICE 
2014** 
BAP 
2016** 
Aripiprazole 1 1 1 - 3 
Asenapine 1 3 1 - 3 
Cariprazine 1 - 3 - 3 
Paliperidone 1 3 1 - 3 
Quetiapine 1 3 1 1 1 
Risperidone 1 1 1 1 1 
Valproate 1 1 1 1 2 
Carbamazepine 2 3 2 - 3 
Haloperidol 2 3 2 1 1 
Lithium 2 3 1 1 3 
Olanzapine 2 3 1 1 1 
Ziprasidone 2 1 1 - 3 
ECT 3 4 2 - 3 
Oxcarbazepine 4 4 3 - - 
Chlorpromazine 4 3 3 - 3 
Pimozide 4 3 - - 3 
Tamoxifen 4 3 3 - - 
Eslicarbazepine NR  - -  -  - 
Gabapentin NR NR NR NR - 
Lamotrigine NR NR NR NR - 
Licarbazepine NR -  -  -  - 
rTMS NR - - - - 
Topiramate NR NR NR NR - 
Verapamil NR  - -  -  - 
Phenytoin - 3 - - - 
Clozapine  - 4 3 - 3 
Amisulpride  - 4 - - 3 
Clonazepam  - 4 - - - 
Leviracetam  - 4 - - - 
Lorazepam  - 4 - - - 
 
Table 17: Comparison of the detailed algorithm to previously developed guidelines 
for acute mania (the grading is not uniform; instead it reflects the grading utilized by 
individual guidelines and the table aims only to give an image of how different 
guidelines prioritize treatment options) 
Numbers correspond to steps not to efficacy ranking 
* NICE and BAP ordering is on the basis of line of treatment 
** Step 2 in the WFSBP guideline would be a combination of two grade “1” 
recommended medication, or switch from one grade “1” medication to another. 
ECT: Electroconvulsive treatment 
rTMS: repetitive Transcranial Magnetic Stimulation 
NR: Not Recommended 
 
  
 by guest on N
ovem
ber 17, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pt
ed
 M
an
us
cr
ipt
 125 
agent/modality overall  BD-I 
BD-
II 
Depressive 
core 
Comorbid 
anxiety 
Rapid  
cycling 
Recommended 
Dosage (mg/day) 
Quetiapine 1 3 3 3 3 2 300-600 mg/day 
Lurasidone 1 - - 3 3 - 20-120 mg/day 
OFC 2 2 - 3 - - 6+25; 6+50; 12+50 mg/day 
Escitalopram - - 1 - - - 10 mg/day 
Fluoxetine 2 - 3 - - - 20-80 mg/day 
Olanzapine 2 4 - 3 - - 5-20 mg/day 
Carbamazepine 3 - - - - - 300-800 mg/day 
Valproate 3 3 5 3 3 4 
500-2500 mg/day (50-100 
mcg/ml) 
Aripiprazole 3 3 - - - - 5-30 mg/day 
Imipramine  3 - - - - - 75-300 mg/day 
Lamotrigine 3 3 3 3 - - 50-200 mg/day 
Phenelzine  3 - - - - - 15-90 mg/day 
Lithium 4 - 4 - 5 3 600-1800 mg/day 
Tranylcypromine   4 4 4 - - - 20-30 mg/day 
Venlafaxine  4 4 4 - - - 75-225 mg/day 
Paroxetine 5 5 5 - 3 5 20 mg/day 
Ziprasidone 5 5 - - 5 -  
Gabapentin 5 - - - - -  
rTMS 5 - - - - -  
Risperidone - - - - 5 -  
 
Table 18: Level of recommendation concerning monotherapy in acute bipolar 
depression, in comorbid conditions and rapid cycling patients and recommended 
dosages for medication options 
OFC: olanzapine-fluoxetine combination, rTMS: repetitive Transcranial Magnetic 
Stimulation 
NR: not recommended 
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agent/modality MS Cbz Lam Li Val 
Lurasidone 2 - - - - 
Modafinil  2 - - - - 
Pramipexole  2 - - - - 
Pioglitazone  - - - 2 - 
Armodafinil  4 - - - - 
Ketamine  4 - - - - 
Paroxetine 5 5 - 5 5 
Ziprasidone 5 - 5 5 5 
Bupropion 5 - - - - 
Celecoxib   5 - - - - 
Levetiracetam  5 - - - - 
Levothyroxine (L-T4) 4 - - - - 
Risperidone 5 - - - - 
Lithium - - 2 - - 
Memantine  - - 5 - - 
FEWP - 4 - - - 
Oxcarbazepine - - - 4 - 
Lamotrigine - - - 2 - 
L-sulpiride  - - - 3 - 
Fluoxetine - - - 4 - 
Agomelatine 5 - - 5 5 
Aripiprazole - - - 5 - 
Imipramine  - - - 5 - 
 
Table 19: Level of recommendation concerning combination treatment in acute 
bipolar depression 
MS: mood stabilizer  
Cbz: carbamazepine 
Lam: lamotrigine 
Val: valproate 
FEWP: Free and Easy Wanderer Plus (herbal agent)
 by guest on N
ovem
ber 17, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pt
ed
 M
an
us
cr
ipt
 127 
Steps  First  Second  Third  Fourth  Fifth  
Overall  
Start with quetiapine 
or lurasidone  
Consider CBT as add-
on to medication and 
according to the 
patient preference and 
to availability. Never 
consider CBT as 
monotherapy 
Add a mood stabilizer on 
lurasidone,  modafinil or 
pramipexole 
Lithium plus lamotrigine, or 
pioglitazone*  
Olanzapine monotherapy or 
OFC 
 Valproate, aripiprazole, 
imipramine, phenelzin, 
carbamazepine or 
lamotrigine monotherapy 
 
Lithium plus  L-sulpiride  
 
Tranylcypromine or lithium 
monotherapy 
 
Venlafaxine preferably in 
combination with an 
antimanic agent 
 
Armodafinil or ketamine on 
a mood stabilizer 
 
Lithium plus fluoxetine 
 
Carbamazepine plus FEWP 
 
Mood stabilizer plus 
levothyroxine (L-T4) 
 
Lithium plus oxcarbazepine 
 
 
 
ECT or various 
combinations of 
medication according to 
anecdotal knowledge or 
the personal experience 
of the therapist 
 
Rapid cycling  If BD-I start with valproate, in 
BD-II with lithium 
 
No rapid 
cycling 
If BD-II start with escitalopram 
or fluoxetine monotherapy 
 
Comorbid  
anxiety 
Add paroxetine, quetiapine, 
valproate or lurasidone and 
consider Mindfulness based 
interventions as add-on to these 
agents 
 
 
Table 20: Precise algorithm to treat acute bipolar depressive episodes on the basis of specific clinical characteristics 
*  no wide clinical experience   
 
CBT: Cognitive Behavioral Treatment 
Cbz: Carbamazepine 
ECT: Electroconvulsive therapy 
FEWP: Free and Easy Wanderer Plus (herbal agent) 
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IPSRT: InterPersonal and Social Rhythms Therapy 
Lam: Lamotrigine 
Li: Lithium 
MS: Mood Stabilizer 
OFC: Olanzapine Fluoxetine Combination 
rTMS: repetitive Transcranial Magnetic Stimulation 
Val: Valproate 
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 CINP 
2016 
WFSBP 
2013* 
CANMAT  
& 
ISBD 2013 
NICE 
2014** 
BAP 
2016** 
Lurasidone  1 - 2 - 1 
Quetiapine  1 1 1 1 1 
Escitalopram  2*** - - - 3 
Fluoxetine  2*** 1 - - 3 
Olanzapine 2 1 3 1 1 
OFC 2 1 1 1 1 
Aripiprazole  3 NR NR - - 
Imipramine 3    4 
Lamotrigine  3 1 1 1 2 
Phenelzin 3    - 
Valproate  3 1 2 1 - 
Carbamazepine  3 1 3 - - 
Lithium  4 1 1 1 3 
Tranylcypromine  4 - - - 4 
ECT 5 - 3 - 5 
Gabapentin NR - NR - - 
Leviracetam - - NR - - 
L-thyroxine - - - - - 
Paroxetine  NR NR - - 3 
Risperidone  - - NR - - 
rTMS NR - - - - 
Ziprasidone  NR NR NR - - 
 
Table 21: Comparison of the presise algorithm to previously developed guidelines for 
acute bipolar depression concerning monotherapy (the grading is not uniform; instead 
it reflects the grading utilized by individual guidelines and the table aims only to give 
an image of how different guidelines prioritize treatment options) 
Numbers correspond to steps not to efficacy ranking 
*WFSBP: Recommendation only reflects monotherapy not considering evidence 
derived from combination treatment (except OFC) 
** NICE and BAP ordering is on the basis of line of treatment 
*** against BD-II depression 
NICE ordering is on the basis of line of treatment 
ECT: Electroconvulsive treatment 
OFC: Olanzapine-Fluoxetine Combination 
rTMS: repetitive Transcranial Magnetic Stimulation 
NR: Not Recommended 
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agent/modality 
index 
episode 
Enriched 
sample 
Manic  depressive Mixed Rapid cycling 
Recommended 
dosage 
Quetiapine m/d yes 2 2 - Quet+ Val/Li (3) 300-800 mg/day 
Olanzapine m Yes/No 2 2 2 - 5-20 mg/day 
  
Lithium m/d No 2 3 - Li, Li + Cbz (3) 0.6-1.2 mEq/l 
Lamotrigine m/d yes  3 2 - 5 50-400 mg/day 
  
Aripiprazole m yes 1 5 - 3 10-30 mg/day 
RLAI m yes 1 5 - RLAI+TAU (3) 25-50 mg/biweekly 
Paliperidone m yes  2 5 - - 3-12 mg/day 
Valproate m yes 4 3 - - 45-100 mg/l 
Ziprasidone m yes - - - - 80-160 mg/day 
Perphenazine  m yes  - - - -  
  
Imipramine  d ? 5 5 - -  
Fluoxetine d Yes  - 2 - - 10-40 mg/day 
CBT d No - - - -  
N-acetyl cysteine d Yes  - - - -  
Carbamazepine - - 4 4 - Li + Cbz (3) 4-12 mg/l 
 
Table 22: Level of recommendation concerning monotherapy during the maintenance phase and in relationship to index episode, composition of 
the sample, presence of rapid cycling and the efficacy in the prevention of mainic, mixed or depressive episodes as well as recommended 
dosages  
Enriched sample: the sample is enriched on the basis of remission after treatment with the agent under consideration during the acute phase 
(index episode) 
CBT: Cognitive Behavioural Therapy,    Cbz: carbamazepine,  Li: lithium, Quet: quetiapine, RLAI: Risperidone Long Acting Injection, 
TAU: Treatment As Usual,   Val: valproate 
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agent/modality MS Cbz Lam Li Val 
Quetiapine 1 - - - - 
Aripiprazole 2 - 5 - 5 
RLAI 2 - - - - 
CBT 2 - - - - 
Phenytoin  2 - - - - 
Paroxetine 3 - - - - 
Psychoeducation 3 - - - - 
Olanzapine 4 - - - - 
Ziprasidone 4 - - - - 
N-acetyl cysteine 4 - - - - 
Imipramine - - - 5 - 
Memantine  5 - - - - 
Oxcarbazepine - - - 5 - 
Lithium - - 4 - - 
Perphenazine  5 - - - - 
 
Table 23: Level of recommendation concerning combination treatment during the 
maintenance phase  
CBT: Cognitive Behavioral Therapy,    Cbz: carbamazepine, Lam: lamotrigine 
Li: lithium,  MS: mood stabilizer,  RLAI: Risperidone Long Acting Injection,  
Val: valproate 
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Step First Second  Third  Fourth  Fifth  
Depressive predominant 
polarity or  
 
No predominant polarity 
Quetiapine or olanzapine 
monotherapy 
Add fluoxetine or lamotrigine Add N-acetylcysteine  
If depressive episodes keep 
emerging add an agent with 
proven efficacy against 
acute bipolar depression no 
matter whether it has proven 
maintenance efficacy. 
Consider adding venlafaxine 
or lithium plus lamotrigine. 
 
Consider any combinations 
from steps 1-4 which have 
not been tried 
Consider maintenance ECT 
Various combinations of 
medication according to 
anecdotal knowledge or the 
personal experience of the 
therapist 
 
Consider IPSRT as add-on 
to medication on the basis 
of clinical judgement of the 
therapist and according to 
the patient preference and 
to availability. Never 
consider IPSRT as 
monotherapy 
 
Manic predominant 
polarity  
Start with lithium, aripiprazole, 
olanzapine, paliperidone, 
quetiapine or risperidone 
(including RLAI) monotherapy  
 
Add lithium on the first step 
option  
 
Lithium plus carbamazepine  
 
Quetiapine plus lithium or 
valproate 
 
If manic episodes keep 
emerging add RLAI on 
current treatment if not 
already in place 
Add N-acetylcysteine 
 
If manic episodes keep 
emerging add an agent 
which has proven efficacy 
against acute mania no 
matter whether it has proven 
maintenance efficacy. 
Consider haloperidol or 
lithium plus lamotrigine 
Mixed episodes are 
frequent 
Olanzapine or aripiprazole plus 
a mood stabilizer 
Add valproate, 
carbamazepine or 
lamotrigine on second step 
treatment  
Proceed to next step 
Rapid cycling Lithium monotherapy 
All cases 
Consider CBT or psychoeducation as add-on to medication on the basis of clinical judgement of the therapist and according to the patient preference and to 
availability. Never consider CBT or psychoeducation as monotherapy 
 
Table 24: Precise algorithm to treatment during the maintenance phase for bipolar disorder on the basis of specific clinical characteristics 
 
CBT: Cognitive Behavioral Treatment 
Cbz: Carbamazepine 
ECT: Electroconvulsive therapy 
IPSRT: InterPersonal and Social Rhythms Therapy 
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Lam: Lamotrigine 
Li: Lithium 
MS: Mood Stabilizer 
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 CINP 
2016 
WFSBP 
2013* 
CANMAT  & 
ISBD 2013 
NICE 
2014** 
BAP 
2016** 
Aripiprazole  1 1 1 - 3 
Lithium 1 1 1 1 1 
Olanzapine 1 2 1 1 2 
Paliperidone 1 3 2 - 3 
Quetiapine 1 1 1 1 2 
Risperidone 1 2 - - 3 
RLAI 1 - 1 - 2 
OFC 2 - 2 - - 
Lamotrigine 2 1 1 - 2 
Carbamazepine 3 4 2 - 2 
Valproate  3 3 1 1 2 
Haloperidol 4 - - - 3 
Venlafaxine 4 - - - - 
ECT 5 4 3 - - 
Ziprasidone 5 3 - - 3 
Continue most recent episode treatment NR - - 1 - 
Antidepressants - 3 NR - 4 
Asenapine  - 4 3 - 3 
Gabapentine - 4 NR NR - 
Topiramate - 4 NR - - 
 
Table 25: Comparison of the presise algorithm to previously developed guidelines for 
maintenance phase concerning monotherapy (the grading is not uniform; instead it 
reflects the grading utilized by individual guidelines and the table aims only to give an 
image of how different guidelines prioritize treatment options) 
Numbers correspond to steps not to efficacy ranking 
*WFSBP: Recommendation grades and subsequent positioning could be either based 
on efficacy in the prevention of mania, depression or any episode.  Thus, numbers do 
not reflect the sequence of treatment in an individual patient. 
** NICE and BAP ordering is on the basis of line of treatment 
RLAI: Risperidone Long-Acting Injectable 
OFC: Olanzapine-Fluoxetine Combination 
ECT: Electro-Convulsive Treatment 
NR: not recommended 
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Figure 1 
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Figure 2 
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